**CURRICULUM VITAE**



**Eugene Anthony Woltering, MD, FACS**

**Current Title:** James D. Rives Professor of Surgery and Neurosciences

**Business Address:** Louisiana State University Health Sciences Center

Department of Surgery

1542 Tulane Avenue, Room 747

New Orleans, LA 70112

**Business Telephone and Fax:** T: (504)-464-8500; F: (504)-464-8525

**Business Email Address:** ewolte@lsuhsc.edu

**Citizenship:** US Citizen

**Education:**

**Undergraduate**

1971-1974 Case Western University – Cleveland, OH

Bachelor of Arts – cum laude

**Graduate/Medical**

1975 Ohio State University School of Medicine

Columbus, OH

**Internship**

1975-1976 Vanderbilt University Affiliated Hospitals

Nashville, TN

**Residency**

1976-1982 Vanderbilt University, Affiliated Hospitals

Nashville, TN

Chief Resident: 1981-1982

**Post-Doctoral** **Fellowship**

1982-1984 Fellow Division of Surgical Oncology

Ohio State University School of Medicine

Columbus, OH

**Clinical Fellowship**

1983-1984 Clinical Fellow American Cancer Society

Division of Surgical Oncology

Ohio State University School of Medicine

Columbus, OH

**Other**

1977-1979 Clinical Associate

Surgery Branch

National Cancer Institute

National Institutes of Health

Bethesda, MD

**Certification:**

1984: American Board of Surgery

Certificate #29098: Expires July 1, 2014

**Licensure:**

Ohio #35-03-8654-W: Expires October 10, 2013

Oregon #14688: Expires December 31, 2013

Louisiana #09723R: Expires February 28, 2013

**Academic, Professional, and Research Appointments:**

**Academic:**

1982-1984 Clinical Instructor Division of Surgical Oncology

Ohio State University

Columbus, OH

1984-1985 Assistant Professor of Surgery Division of Surgical Oncology

Ohio State University

Columbus, OH

1985-1986 Junior Faculty/Clinical Fellow

American Cancer Society

1986-1989 Assistant Professor of Surgery Division of Surgical Oncology

Oregon Health and Sciences University

Portland, OR

1989-1993 Associate Professor of Surgery Division of Surgical Oncology

Oregon Health and Sciences University

Portland, OR

1993-present The James D. Rives Professor of Surgery and Neuroscience

Chief of Surgical Endocrinology Department of Surgery

Louisiana State University Health Sciences Center

New Orleans, LA

1995-present The James D. Rives Professor of Surgery and Neuroscience

Chief of Surgical Endocrinology Department of Surgery

Joint appointments in the LSU Neuroscience Center of Excellence and the Stanley S. Scott Cancer Center

Louisiana State University Health Sciences Center

New Orleans, LA

2003-present Chief of Surgical Oncology Department of Surgery

Louisiana State University Health Sciences Center

New Orleans, LA

**Professional:**

1993-present Active Staff Medical Center of Louisiana at New Orleans

New Orleans, LA

1995-present Active Staff Ochsner Medical Center-Kenner

Kenner, LA

**Research:**

1998-present Director of Surgical Research Department of Surgery

Louisiana State University Health Sciences Center

New Orleans, LA

**Membership in Professional Organizations:**

H. William Scott, Jr. Society: Member

American Medical Association: Member

American Board of Surgery: Member

Southwest Oncology Group: Member

National Surgical Adjuvant Breast and Bowel Project (NSABP): Member

Society of University Surgeons: Member

North Pacific Surgical Association: Member

Collegium Internationale Chirurgiae Digestivae: Member

Pacific Coast Surgical Society: Member

American College of Surgeons: Fellow

American Association of Endocrine Surgeons: Member

The Pancreas Club: Member

Society of Surgical Oncology: Member

Robert M. Zollinger Surgical Society: Member

Southeastern Surgical Society: Member

American Association of Clinical Endocrinologists: Member

American College of Surgeons-Louisiana Chapter: Member

Southern Medical Association: Member

New Orleans Surgical Society: Member

American Physiological Society: Member

American Association for Cancer Research: Member

Louisiana Geriatrics Society: Member

North American Neuroendocrine Tumor Society: Member

European Neuroendocrine Tumor Society: Member

**Awards and Honors:**

1979 President’s Award for the Best Scientific Paper; Southern Thoracic Surgical Association

1989 Annual Science Writers Seminar; American Cancer Society

1990-2006 Novartis Oncology Distinguished Speakers Bureau

1993 American Cancer Society Oncology Consult Program

1994-1999 Mallinckrodt Medical, Inc. Distinguished Speakers Bureau

1994-1999 Sandoz Pharmaceuticals Corp. Distinguished Speakers Bureau

1994-2002 National Information Network Advisory Council

1995 Innovator of the Year, Louisiana Partnership for Technology and Innovation

1997 Dr. Robert D. & Alma W. Moreton Original Research Award for 1997; Southern Medical Association

1998 John & Julia Sawyers Research Award; Vanderbilt University, Nashville, TN

2005-20012 Castle Connoly America’s Top Doctors for Cancer

2008 Innovator of the Year, New Orleans City Business, New Orleans, LA; Patient’s Choice Award

**TEACHING EXPERIENCE AND RESPONSIBILITIES**

**Course/Clerkship/Residency or Fellowship/CME Directorships**

Director of Surgical Research

**Formal Course Responsibilities**

Responsible for residents participating in research during their five year residency.

**Departmental/Interdisciplinary Teaching Conferences**

Chair the Department of Surgery’s weekly Tumor Board conference.

**Undergraduate, Medical, or Graduate Students Trained:**

Kevin Gibson (2008). Lanminh Pham (2007). Mark Stadler (2007). Islam Elnagar (2005). Rishi Agarwal (2004). David Story (2003). Marc Matrana (2003). Sean Weiss (2002 and 2001). Susan Hughey (2002). John Lyons (2001). Bruce Torrance (2000).

**RESEARCH AND SCHOLARSHIP**

**Grants and Contracts:**

**Funded**

**Schering-Plough**: Evaluation of Angiogenesis Inhibitors in Human Tissue Model: INTRON (Interferon) and PEG-INTRON

Dates of Approved Project: 01/01/2001-12/31/2001

Role: Principle Investigator

**Encelle, Inc.**: Development of a Novel Bioassay for Testing the Biologic Activity of E-Matrix In Vitro

Dates of Approved Project: 6/18/2001-6/17/2002

Role: Principle Investigator

**NSBP (National Surgical Adjuvant Breast and bowel Project) Foundation, Inc.**

Dates of Approved Project: 02/01/2003-01/31/2004

Role: Site Principle Investigator

**Novartis**: Use of an In Vitro Model to Characterize the Antiangiogeneic Activity of Epothilone

Dates of Approved Project: 04/01/2003-07/21/2003

Role: Principle Investigator

**Ullman Medical Inc.**: Identification of Growth Inhibitory Compounds in Fig (Ficus Carica) Latex and Fruit Extracts

Dates of Approved Project: 12/15/2006-12/17/2007

Amount of Award: $157,213

Role: Principle Investigator at LSUHSC

**National Institutes of Health, National Cancer Institute**: Anti-Angiogeneic Properties of Sweet Leaf Tea Extract (R21)

Dates of Approved Project: 8/1/2007-7/31/2009

Amount of Award: $105,081

Role: Principle Investigator

**Tulane LSUHSC; Louisiana Board of Regents Grant**: Design, Delivery & Development of Therapeutic Peptide

Dates of Approved Project: 10/23/2007-7/21/2010

Amount of Award: $18,700

Role: Principle Investigator for LSUHSC

**LSU Idea Grant**: Human Carcinoid Tumor Dysregulation of Dendritic Cell Function

Date of Approved Project: 11/01/2008

Amount of Award: $57,000

Role: Co-Principle Investigator

**Pennington Biomedical Research Pilot Grants:** Modulation of Angiogenic Gene Expression by Black Raspberry Extract

Dates of Approved Project: 08/01/2011-08/01/2012

Amount of Award: $34,967

Role: Principle Investigator

**AAA Corporation**: LU DOTA-TATE as a Therapy for NETs

Date of Approved Project: 8/01/2012

Role: Sub-Investigator

**Non-funded applications (last three years)**

**American Association for Cancer Research**: Gene Expression in Neuroendocrine Tumor-Associated Angiogenesis

Dates of Proposed Project: 2/01/2011-1/31/2013

Role: Principle Investigator

**Pending funding**

**NCI SPORE Grant**: Mechanisms of Dietary and Drug Interaction in Human Angiogenesis

Dates of Approved Project: Pending

Role: Principle Investigator for LSUHSC

**Journal Publications:**

**Refereed**

1. Javadpour N, **Woltering EA**, McIntosh CL: Thoracoabdominal-median sternotomy for resection of primary adrenal carcinoma extending into inferior vena cava and hepatic vein. Urology, 12(6): 626-627, 1978.
2. **Woltering EA**, Thorpe WP, Reed JK, Rosenburg SA: Split thickness skin grafting of the plantar surface of the foot after wide excision of neoplasms of the skin. Surg Gynecol Obstet, 149(2): 229-232, 1979.
3. **Woltering EA**, Emmott RG, Javadpour N, Brennan MF: Differences in cell surface antigen with parathyroid adenoma and hyperplasia. Surgical Forum, 30:107-109, 1979.
4. Javadpour N, **Woltering EA**, Soares T: Simultaneous Measurement of Tumor Cytosol and Peripheral Serum Levels of Human Chorionic Gonadotropin and Alpha-fetoprotein in Testicular Cancer. Invest Urol, 18(1):11-12, 1980.
5. **Woltering EA**, Flye MW, Huntley S, Kapp P, Dwyer A, McFlees B: Evaluation of Bupivacaine Nerve Blocks in the Modification of Pain and Pulmonary Function Changes After Thoracotomy. Ann Thorac Surg, 30(2):122-127, 1980.
6. **Woltering EA**, Knox RD, Javadpour N, Soares T, Chen HC: Detection of Human Chorionic Gonadotropin in Fresh and Formalin-fixed Testicular Tumor Tissue. Comparison of sensitivity of immunoperoxidase to radioimmunoassay. Urology, 16(2): 215-218, 1980.
7. Javadpour N, **Woltering EA**, Brennan MF: Adrenal Neoplasms. Current Prob Surg. 17(1):1-52, 1980.
8. **Woltering EA**, Emmott RC, Javadpour N, Marx SJ, Brennan MF: ABO (H) Cell Surface Antigens in Parathyroid Adenoma and Hyperplasia. Surgery, 90(1):1-9, 1981.
9. Lotze MT, Duncan MA, Gerber LH, **Woltering EA**, Rosenburg SA: Early Versus Delayed Shoulder Motion Following Axillary Dissection: A Randomized Prospective Study. Ann Surg, 193(3): 288-295, 1981.
10. Ellison EC, **Woltering EA**, Hitchcock C, Nelson K, Howe B, Stephens R, Carey LC, O’Dorisio T: The Effect of Calcium on Vasoactive Intestinal Peptide Release from an Islet Cell Tumor Associated with the Verner-Morrison Syndrome. Surg Forum, 34:227-229, 1983.
11. **Woltering EA**, Tuttle SE, James AG, Sharma HM: ABO (H) Cell Surface Antigens in Benign and Malignant Parotid Neoplasms. J Surg Oncol, 24(3): 177-179, 1983.
12. Flye MW, **Woltering EA**, Rosenburg SA: Aggressive Pulmonary Resection for Metastatic Osteogenic and Soft Tissue Sarcomas. Ann Thorac J Surg, 37:123-127, 1984.
13. Bluett M, **Woltering EA**, Adkins RB: Management of Penetrating Hepatic Injury: A Review of 102 Consecutive Patients. Am Surg, 50:132-142,1984.
14. Adkins RB, Whiteneck J, **Woltering EA**: Carcinoma of the Breast in the Extremes of Age. South Med J, 77:553-559, 1984.
15. **Woltering EA**, Dumond D, Ferara J, Farrar WB, James AG: A Method for Intraoperative Identification of the Recurrent Laryngeal Nerve. Am J Surg, 148(4): 438-440, 1984.
16. Ellison EC, O’Dorisio MS, O’Dorisio TM, Sparks J, Vasallo L, Woltering EA: Failure of Secretin to Stimulate Gastrin Release and Adenylate Cyclase Activity in Gastrinoma In Vitro. Surgery, 96(6):1019-1026, 1984.
17. Dwyer AJ, Reichert CM, **Woltering EA**, Flye MW: Diffuse Pulmonary Metastasis in Melanoma: Radiographic-Pathologic Correlation. Am J Roentgenol, 143(5): 983-984, 1984.
18. Buckspan R, **Woltering EA**, Waterhouse G: Pancreatitis Induced by Intravenous Infusion of a Fat Emulsion in an Alcoholic Patient. South Med J, 77:251-252, 1984.
19. Tuttle SE, **Woltering EA**, Sharma H: Monoclonal Antibody Localization of A, B, and H Blood Group Antigen in Human Tumors. Lab Invest, 50:62, 1984.
20. Adkins RB, Whiteneck JM, **Woltering EA**: Penetrating Chest Wall and Thoracic Injuries. Am Surg, 51(3): 140-148, 1985.
21. **Woltering EA**, Ellison C, O’Dorisio TM, Hitchcock C, Roberts FK, Stephens R, Sparks J, Carey LC: Gastrin Release from Dispersed Gastrinoma Cells: Effects of Calcium and Calcium Ionophore (A23187). J Surg Res, 39(4): 331-337, 1985.
22. James AG, Crocker S, **Woltering EA**, Ferrara J, Farrar WB: The Recurrent Laryngeal Nerve: A Simple Method for Identifying and Testing. Surg Gynecol Obstet, 161:185-186, 1985.
23. **Woltering EA**, O’Dorisio TM, Mekhjian HS, Ellison EC, Dyben T, Howe BA, Tuttle SE, Minton JP: The Response of a Non-Functional VIP and Somatostatin-Containing Tumor to Tolbutamide In Vitro. Scand J Gastroenterol, 21: (supp. 119) 129-135, 1986.
24. Ellison EC, O’Dorisio TM, **Woltering EA**, Sparks J, Mekhjian HS, Fromkes JJ, Carey LC: Suppression of Gastrin and Gastric Acid Secretion in the Zollinger-Ellison Syndrome by Long-Acting Somatostatin (SMS 201-995). Scand J Gastroenterol, 21: (supp. 199): 206-211, 1986.
25. Benson GD, O’Dorisio TM, Ellison EC, **Woltering EA**, Morrison AB: Control of Watery Diarrhea Syndrome in a Patient with a Vasoactive Intestinal Peptide-Secreting Tumor Using SMS 201-995 and Dexamethasone. Scand J Gastroenterol, 21: (supp. 119): 170-176, 1986.
26. **Woltering EA**, Ellison EC, O’Dorisio TM, Sparks J, Howe B, Dyben T: Somatostatin-like Peptides Alter Calcium but not Secretin Sensitivity of Gastrinoma Cells. J Surg Res, 40(6): 605-610, 1986.
27. McCabe DP, O’Dwyer PJ, Sickle-Santanello BJ, **Woltering EA**, Issa HA, James AG: Polar Solvents in the Chemoprevention of Dimethylbenzanthracene-Induced Rat Mammary Cancer. Arch Surg 121:1455-59, 1986.
28. O’Dwyer PJ, McCabe DP, Clausen K, Sickle-Santanello BJ, Klein J, **Woltering EA**, Martin EW, Jr.: Chemoprevention in Experimental Colon Cancer. Surg Forum, 37:436-438, 1986.
29. Elkhammas EA, Gower WR, Jr., **Woltering EA**, O’Dorisio TM, Sparks J, Fabri PH, Ellison EC: Effect of Secretin on Gastrin Release from Gastrinoma Cells In Vitro. Surgery, 100(6): 948-953, 1986.
30. Ellison EC, O’Dorisio TM, Sparks B, Mekhjian HS, Fromkes JJ, **Woltering EA**, Carey LC: Observations on the Effect of a Somatostatin Analog in the Zollinger-Ellison Syndrome: Implications for the Treatment of APUDomas. Surgery, 100(2): 437-444, 1986.
31. Ellison EC, Gower WR, Elkhammas E, **Woltering EA**, Sparks J, O’Dorisio TM, Fabri PJ: Characterization of the In Vivo and In Vitro Inhibition of Gastrin Secretion from Gastrinoma by a Somatostatin Analogue (SMS 201-995). Am J Med, 81(6B): 56-64, 1986.
32. Pommier RF, **Woltering EA**, Campbell JR, Fletcher WS: Hepatic Resection for Primary and Secondary Neoplasms of the Liver. Am J Surg, 153(5):428-433, 1987.
33. O’Dorisio TM, Mekhjian HS, Ellison TM, O’Dorisio MS, Gaginella TS, **Woltering EA**: Role of Peptide Radioimmunoassay in Understanding Peptide-Peptide Interactions and Clinical Expression of Gastroenteropancreatic Endocrine Tumors. Am J Med, 82 (Supp. 5B): 60-67, 1987.
34. Pommier RF, **Woltering EA**, Keenan EJ, Fletcher WS: The Mechanism of Hormone Sensitive Breast Cancer Progression on Antiestrogen Therapy: Implications for Treatment and Protocol Planning. Arch Surg 122 (11): 1311-1316, 1987.
35. Pommier RF, **Woltering EA**, Milo G, Fletcher WS: Synergistic Cytotoxicity between Dimethyl Sulfoxide and Antineoplastics against Ovarian Cancer In Vitro. Surg Forum, (38): 475-477, 1987.
36. Pommier RF, **Woltering EA**, Milo G, Fletcher WS: Cytotoxicity of Dimethyl Sulfoxide and Antineoplastic Combinations Against Human Tumors. Am J Surg, 155(5): 672-676, 1988.
37. **Woltering EA**, Mozell EJ, O’Dorisio TM, Ellison EC, Fletcher WS, Howe B: Suppression of Primary and Secondary Peptides with Somatostatin Analog. Surg Gyn & Obstet, 167:453-462, 1988.
38. Brown DA, Pommier RF, **Woltering EA**, Fletcher WS: Non-Anatomic Hepatic Resection for Secondary Hepatic Tumors with Special Reference to Hemostatic Technique. Arch of Surg, 123:1063-1066, 1988.
39. Pommier RF, **Woltering EA**, Milo G, Fletcher WS: Synergistic Cytotoxicity Between Dimethyl Sulfoxide and Antineoplastic Agents Against Ovarian Cancer In Vitro. Am J Ob/Gyn, 159: 848-852, 1988.
40. O’Dwyer PJ, McCabe DP, Sickle-Santanello BJ, **Woltering EA**, Clasen K, Martin EW, Jr.: Use of Polar Solvents in Chemoprevention of 1, 2, Dimethylhydrazine-Induced Colon Cancer. Cancer, 62:944-948, 1988.
41. Pommier RF, **Woltering EA**, Fletcher WS: Synergistic Cytotoxicity of Dimethyl Sulfoxide-Antineoplastic Combinations Against P388 Leukemia in CD-F1 Mice. Surgical Forum, 39:471-473, 1988.
42. Morrissey TB, **Woltering EA**: Sodium Oxalate Corrects Calcium Interference in Lowry Protein Assay. J Surg Res, 47(3): 273-275, 1989.
43. Williams ST, **Woltering EA**, O’Dorisio TM, Fletcher WS: Effect of Octreotide Acetate on Pancreatic Exocrine Function. Am J Surg, 157:459-462, 1989.
44. Mozell E, **Woltering EA**, O’Dorisio TM, Fletcher WS, Sinclair A, Hill D: Effect of Somatostatin Analog on Peptide Release and Tumor Growth in the Zollinger-Ellison Syndrome. Surg Gyn & Obstet. 170: 474-484, 1990.
45. Mozell EJ, O’Dorisio TM, Phillipson BE, Fletcher J, Fletcher WS, Howe B, Hill D, Rhea D, **Woltering EA**: Adult Onset Nesidioblastosis: Response of Glucose, Insulin and Secondary Peptides to Therapy with Sandostatin, Am J Gastro 85:(2) 181-188, 1990.
46. Lebredo L, **Woltering EA**, Moseley HS, Bos G, Small K, Fletcher WS: Results of Cisplatin Hyperthermic Isolation Perfusion with Dose Escalation for Extremity Sarcomas. Regional Cancer Treatment 2: 120-124,1990.
47. **Woltering EA**, O’Dorisio TM, Williams ST, Lebredo L, Fletcher WS: Treatment of Neuroendocrine Gastrointestinal Disorders with Octreotide Acetate. Metabolism 39(9) Suppl. 2: 176-179, 1990.
48. Richards WO, Geer R, O’Dorisio TM, Robarts T, Parish KL, Rice D, **Woltering EA**, Abumrad NN: Octreotide Acetate Induces Fasting Small Bowel Motility in Patients with Dumping Syndrome. J Surg Res, 49:483-487, 1990.
49. Geer RJ, Richards WO, O’Dorisio TM, **Woltering EA**, Williams S, Rice D, Abumrad NN: Efficacy of Octreotide Acetate in Treatment of Severe Post gastrectomy Dumping Syndrome. Ann Surg, 212 (6): 678-688, 1990.
50. Mozell E, **Woltering EA**, O’Dorisio TM, Stenzel P, Rosch J: Functional Endocrine Tumors of the Pancreas: Clinical Presentation, Diagnosis and Treatment. Current Problems in Surgery, 27(6):301-386, 1990.
51. **Woltering EA**, Barrie R, O’Dorisio TM, Arce D, Ure C, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin Analogs Inhibit Angiogenesis in the Chick Chorioallantoic Membrane. J. Surg. Res, 50:245-251, 1991.
52. Pommier R, **Woltering EA**: Follow-Up of Patients After Primary Colorectal Cancer Resection. Seminars in Surg. Onc, 7:129-132, 1991.
53. Hajarizadeh H, Mueller CR, **Woltering EA**, Small K, Fletcher WS: Phase I-II Trial of Hyperthermic Isolated Limb Perfusion with Cisplatin in the Treatment of High Risk Malignant Melanoma of the Extremities. Melanoma Res, 1:55-61, 1991.
54. Mueller CR, Ure T, Barrie R, O’Dorisio TM, **Woltering EA**: Acute Gastric PH Changes Alter Intraluminal But Not Serum Peptide Levels. Surgery, 110:1116-1124, 1991.
55. Cramer AB, **Woltering EA**: Chemosensitivity Testing: A Critical Review. Critical Reviews in Clinical Laboratory Sciences 28(5-6): 405-13, 1991.
56. Mozell EJ, **Woltering EA**, O’Dorisio TM: Non-Endocrine Applications of Somatostatin and Octreotide Acetate: Facts and Flights of Fancy. Disease-A-Month, 12:751-848, 1991.
57. Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, **Woltering EA**: Effective Palliative Treatment of Metastatic Carcinoid Tumors with Intra-Arterial Chemotherapy/Chemoembolization Combined with Octreotide Acetate. Am J Surg, 163(5): 479-483, 1992.
58. Mozell EJ, Cramer AJ, O’Dorisio TM, **Woltering EA**: Long Term Efficacy of Octreotide Acetate in the Treatment of Zollinger-Ellison Syndrome. Arch of Surg, 127:1019-1026, 1992.
59. Lebredo L, Barrie R, **Woltering EA**: DMSO Protects Against Adriamycin-Induced Tissue Necrosis. J Surg Res, 53:62-65, 1992.
60. Pommier RF, **Woltering EA**, Milo G, Fletcher WS: Synergistic Cytotoxicity of Combinations of Dimethyl Sulfoxide and Antineoplastic Agents Against P388 Leukemia in CD-F1 Mice. Anti-Cancer Drugs, 3:635-639, 1993.
61. Barrie R, **Woltering EA**, Hajarizadeh H, Mueller C, Ure T, Fletcher WS: Inhibition of Angiogenesis by Somatostatin and Somatostatin-like Compounds is Structurally Dependent. J Surg Res 55:446-450, 1993.
62. Fletcher WS, **Woltering EA**, Moseley HS, Bos G, Lebredo L, Brown D, Small KA: Hyperthermic Isolation Limb Perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin. Cancer Treatment and Research 62:241-4, 1993.
63. Fletcher WS, Pommier RF, **Woltering EA**, Mueller CR, Ash KO, Small KA: Pharmacokinetics and Results of Dose Escalation in Cisplatin Hyperthermic Isolation Limb Perfusion (HILP). Ann Surg Oncol 1(3):236-243, 1994.
64. Ogden BE, Martin, Jr. MA, Hall AS, **Woltering EA**, Bryant RE: Octreotide Does Not Alter Endotoxin Lethality in Mice or Endotoxin-Induced Suppression of Human Leukocyte Migration. Life Sciences, 55(15): PL277-285, 1994.
65. Hajarizadeh H, Lebredo L, Barrie R, **Woltering EA**: Protective Effect of Doxorubicin in Vitamin C or Dimethyl Sulfoxide Against Skin Ulceration in the Pig. Ann Surg Oncol 1(5): 411-414, 1994.
66. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, **Woltering EA**: Post-Receptor Signal Transduction Mechanisms Involved in Octreotide-Induced Inhibition of Angiogenesis. Surgery 116(6): 1148-1152, 1994.
67. **Woltering EA**, Barrie R, O’Dorisio TM, O’Dorisio MS, Nance R, Cook DM: Detection of Occult Gastrinomas With 125Iodine Labeled Lanreotide and Intraoperative Gamma Detection. Surgery 116(6):1139-1147, 1994.
68. Pommier RF, **Woltering EA**, Fletcher WS: Changes in Serum Sex Steroid Levels During Megestrol Acetate Therapy. Surg Oncol 3:351-359, 1994.
69. Jones MK, Vetto JT, Pommier RF, Thurmond AS, **Woltering EA**: An Improved Method of Needle Localized Biopsy of Nonpalpable Lesions of the Breast. J Am Coll Surg 178(6): 548-52, 1994.
70. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, **Woltering EA**: Treatment of Metastatic Carcinoid Tumors Using Multimodality Therapy of Octreotide Acetate, Intra-Arterial Chemotherapy, and Hepatic Artery Embolization. Am J Surg, 169(5): 523-528, 1995.
71. Harris AG, O’Dorisio TM, **Woltering EA**, Anthony LB, Burton FR, Geller RB, Grendell JH, Levin B, Redfern JS: Consensus statement: octreotide dose titration in secretory diarrhea. Management Consensus Development Panel. Dig Dis Sci; 40(7): 1464-73, 1995.
72. Luo Qian, Peyman GA, Conway MD, **Woltering EA**: Effect Of A Somatostatin Analog (Octreotide Acetate) On The Growth Of Retinal Pigment Epithelial Cells In Culture. Curr Eye Res. 15: 909-913, 1996.
73. Thompson CS, O’Dorisio TM, **Woltering EA**: Calcium Reverses Octreotide Inhibition of Insulin and Glucagon Levels in Patients with Insulinoma and Glucagonoma. Digestion 57(Suppl 1): 62-68, 1996.
74. Patel PC, **Woltering EA**, Maltese WA, Pelliteri PK: Squamous Cell Carcinoma-Induced Angiogenesis: A Demonstration Using Cultured cells in the Chick Chorioallantoic Membrane Model. Surg Forum XLVII: 786-789, 1996.
75. Watson JC, Gebhardt BM, Alperin-Lea RC, Redmann JG, **Woltering EA**: Initiation of kdr Gene Transcription is Associated with Conversion of Human Vascular Endothelium to an Angiogenic Phenotype. Surg Forum XLVII: 462-464, 1996.
76. Rand-Luby L, Pommier RF, Williams ST, **Woltering EA**, Small KA, Fletcher WS: Improved Outcome of Surgical Flaps Treated with Topical Dimethyl Sulfoxide. J Surg Oncol 224(4): 583-590, 1996.
77. Robertson JE, Westra I, **Woltering EA**, Winthrop KL, Barrie R, O’Dorisio TM, Holmes D: Intravitreal Injection of Octreotide Acetate. J Ocul Pharmacol Ther 13(2): 171-177, 1997.
78. **Woltering EA**, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin Analogs: Angiogenesis Inhibitors with Novel Mechanisms of Action. Invest. New Drugs 15:77-86, 1997.
79. Liang C, Peyman GA, Conway MD, **Woltering EA**: Retinal Toxicity of Intravitreous Octreotide in Rabbits. Can J Ophthalmol 32(4): 229-232, 1997.
80. Watson JC, Redmann JG, Meyers MO, Alperin-Lea RC, Gebhardt BM, Delcarpio JB, **Woltering EA**: Breast Cancer Increases Initiation of Angiogenesis Without Accelerating Neovessel Growth Rate. Surgery 122(2):508-514, 1997.
81. Lum SS, **Woltering EA**, Fletcher WS, Pommier RF: Changes in Serum Estrogen Levels in Women During Tamoxifen Therapy. Am J Surg 173(5): 399-402, 1997.
82. Watson JC, O’Dorisio TM, **Woltering EA**: Octreotide Acetate Controls the Peptide Hypersecretion and Symptoms Associated with the Dumping Syndrome. Asian J Surg 20:283-288, 1998.
83. McCarthy KE, **Woltering EA**, Espenan GD, Cronin M, Maloney TJ, Anthony LB: In Situ Radiotherapy with 111In-pentetreotide: Initial Observations and Future Directions. The Cancer Journal from Scientific American 4:94-102, 1998.
84. Pommier RF, Vetto JT, Billingsly, K, **Woltering EA**, Brennan MF: Comparison of Adrenal and Extraadrenal Pheochromocytomas. Surgery 114(6): 1160-5; discussion 1165:6, 1998.
85. Meyers MO, Anthony CT, Coy DH, Murphy WA, Drouant GJ, Fuselier J, Espenan GD, Maloney TJ, **Woltering EA**: Multiply Radioiodinated Somatostatin Analogs Induce Receptor-Specific Cytotoxicity. J. Surg. Res. 76:154-158, 1998.
86. Schonfeld WH, Elkin EP, **Woltering EA**, Modlin IM, Anthony LB, Villa KF, Zagari M: The Cost-Effectiveness of Octreotide Acetate in the Treatment of Carcinoid Syndrome and VIPoma. International Journal of Technology Assessment in Health Care 14(3): 514-525, 1998.
87. Espenan GD, Nelson JA, Fisher DR, Diaco DS, McCarthy KE, Anthony LB, Maloney TJ, **Woltering EA**: Experiences with High-Dose Radiopeptide Therapy: the Health Physics Perspective. Health Phys. 76(3):225-235, 1999.
88. **Woltering EA**, O’Dorisio MS, Murphy WA, Chen F, Drouant GJ, Espenan GD, Fisher DR, Sharma C, Diaco DS, Maloney TM, Fuselier JA, Nelson JA, O’Dorisio TM, Coy DH: Synthesis and Characterization of Multiply-Tyrosinated, Multiply-Iodinated Somatostatin Analogs. J. Peptide Res. 53:201-213, 1999.
89. Cuntz MC, Levine EA, O’Dorisio TM, Watson JC, Wray DA, Espenan GD, McKnight CA, Meier JR, Weber LJ, Mera R, O’Dorisio MS, **Woltering EA**: Intraoperative Gamma Detection of 125I-Lanreotide in Women with Primary Breast Cancer. Ann Surg Oncol 6(4): 367-372, 1999.
90. Hornick CA, Anthony CT, Hughey S, Gebhardt BM, Espenan GD, **Woltering, EA**: Progressive Nuclear Translocation of Somatostatin Analogs. J Nuclear Med 41(7): 1256-1263, 2000.
91. Meyers MO, Anthony LB, McCarthy KE, Drouant G, Maloney TJ, Espenan GD, **Woltering EA**: High Dose 111In-Pentetreotide Radiotherapy for Metastatic Atypical Carcinoid Tumor. South Med J 93(8):809-811, 2000.
92. Meyers MO, Gagliardi AR, Flattmann GJ, Wang Y, **Woltering EA**: Suramin Analogs Inhibit Human Angiogenesis In Vitro. J Surg Res 91:130-134, 2000.
93. McCarthy KE, **Woltering EA**, Anthony, LB: In Situ Radiotherapy With 111In-Pentetreotide: State of the Art and Perspectives. Q J Nuc Med 44(1):88-95, 2000.
94. Watson JC, Balster DA, Gebhardt BM, O’Dorisio TM, O’Dorisio MS, Espenan GD, Drouant GJ, **Woltering EA**. Growing Vascular Endothelial Cells Express Somatostatin Subtype 2 Receptors. Brit J Cancer 85(2): 266-272, 2001.
95. Gulec SA, Drouant GJ, Fuselier J, Anthony CT, Heneghan J, Delcarpio JB, Coy DH, Murphy WA, **Woltering EA**. Antitumor and Antiangiogenic Effects of Somatostatin Receptor Targeted In Situ Radiation with 111In-DTPA-JIC 2DL. J Surg Res 97(2): 131-137, 2001.
96. Gulec SA, Gaffga CM, Anthony CT, Su LJ, O’Leary JP, **Woltering EA**. Antiangiogenic Therapy with Somatostatin Receptor-Mediated In Situ Radiation. Amer Surg 67(11): 1068-1071, 2001.
97. Jung SP, Siegrist B, Wade M, Anthony CT, **Woltering EA**. Inhibition of Human Angiogenesis with Heparin and Hydrocortisone. Angiogenesis 4:175-186, 2001.
98. Duchesne JC, Mittelbronn MD, Nesbitt, Jr. LT, **Woltering EA**. Image of the Month: Sweet Syndrome. Arch Surg 137: 113-114, 2002.
99. Anthony, LB, **Woltering EA**, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. 111Indium-pentetreotide Prolongs Survival in Gastroenteropancreatic Malignancies. Semin Nucl Med 32(2):123-132, 2002.
100. Schmidt FE, **Woltering EA**, Webb WR, Garcia OM, Cohen JE, Rozans MH. Sentinel Node Assessment in Patients with Carcinoma of the Lung. Ann Thorac Surg 74:870-5, 2002.
101. Jung SP, Siegrist B, Hornick CA, Wang YZ, Wade MR, Anthony CT, **Woltering EA**. Effect of Human Recombinant Endostatin Protein on Human Angiogenesis. Angiogenesis 5:111-118, 2002.
102. Gulec SA, Eckert M, **Woltering EA**. Gamma Probe-Guided Lymph Node Dissection (‘Gamma Picking’) in Differentiated Thyroid Carcinoma. Clin Nuc Med 27(12): 859-861, 2002.
103. **Woltering EA**. Development of Targeted Somatostatin-Based Antiangiogenic Therapy: A Review and Future Perspectives. Cancer Biother Radiopharm 18(4): 605-613, 2003.
104. Cooke HJ, Wang Y-Z, Wray D, O’Dorisio MS, **Woltering EA**, Coy DH, Murphy WA, Christofi F, Ghosh P, O’Dorisio TM. A Multi-Tyrosinated sst 2 Receptor- Preferring Somatostatin Agonist Inhibits Reflex and Immune-Mediated Secretion in the Guinea Pig Colon. Regulatory Peptides 114:51-60, 2003.
105. **Woltering EA**, Lewis JM, Maxwell PJ IV, Frey DJ, Wang Y-Z, Rothermel J, Anthony CT, Balster DA, O’leary JP, and Harrison LH. Development of a Novel in vitro Human Tissue-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs. Ann Surg 237(6): 790-800, 2003.
106. **Woltering EA**. Invited Commentary: Sarr et al. Vapreotide, a Potent, Long-Acting Somatostatin Analog, Does not Decrease Pancreas-Related Complications after Elective Pancreatectomy: A Multicenter, Double-Blind, Randomized Placebo-Controlled Study. J Am Coll Surg 196:556-565, 2003.
107. Anthony CT, Hughey S, Lyons J, Weiss S, Hornick CA, Drouant GJ, Fuselier JA, Coy DH, Murphy WA, **Woltering EA**. The Effect of Drug Dose and Drug Exposure Time on the Binding, Internalization, and Cytotoxicity of Radiolabeled Somatostatin Analogs. J Surg Res 119(1): 1-13, 2004.
108. Hornick C, Myers A, Sadowska-Krowicka H, Anthony C, **Woltering EA**. Inhibition of angiogenic initiation and disruption of newly established human vascular networks by juice of *Morinda Citrifola* (noni), Angiogenesis 6 (2):143-149, 2004.
109. Siegrist B, Anthony C T, Hornick C,. Wade MR, Jung SJ, Wang YZ, and **Woltering EA**. Effect of Human Angiostatin Protein on Human Angiogenesis, Angiogenesis **6** (3): 233-240, 2004.
110. Oberg K, Kvols L, Caplin M, DelleFave G deHerder W, Rindi G, Ruszniewski P, **Woltering EA**, Weidenmann B. Consensus statement on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology 15: 966-973, 2004.
111. Gulec SA, **Woltering EA**. A new in vitro assay for human tumor angiogenesis: three-dimensional human tumor angiogenesis assay. Ann Surg Oncol. 11(1); 99-104, 2004.
112. Stafford SJ, Schwimer J, Anthony CT, Thomson JL, Wang YZ, **Woltering EA**. Colchicine and 2-methoxyesteradiol Inhibit Human Angiogenesis. J Surg Res. 125(1): 104-8. 2005.
113. Boudreaux JP, Putty B, Frey D, **Woltering EA**, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W. Surgical Treatment of Advanced-stage carcinoid Tumors: Lessons Learned. Ann Surg 241(6); 1-8. 2005.
114. Liu Z, Schwimer J, Liu D, Greenway FL, Anthony CT, **Woltering EA**. Black Raspberry Extract and Fractions Contain Angiogenesis Inhibitors. J Agric Food Chem 53; 2909-3915, 2005.
115. **Woltering EA**, Mamikunian PM, Zietz S, Krutzik SR, Go VLW, Vinik AI, Vinik E, O’Dorisio TM, Mamikunian G. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas. 31: 392-400, 2005.
116. Gunn SH, Schwimer JE, Cox M, Anthony CT, O’Dorisio MS, **Woltering EA**. In Vitro Modeling of the Clinical Interactions Between Octreotide and 111In-Pentetreotide: Is There Evidence of Somatostatin Receptor Down regulation? J Nucl Med. 47(2): 354-359, 2006.
117. Lewis JM, Anthony CT, Harrison LH, Ferguson TB, Heck HA, Rubenstein F, Balster DA, **Woltering EA**. Development of a human cardiac tissue-based angiogenesis model. J Surg Res. 135(1): 34-7 2006.
118. Kvols LK, **Woltering EA**. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. Anticancer Drugs. Review 17(6): 601-8, 2006.
119. Stafford SJ, Wright JL, Schwimer J, Anthony CT, Cundiff JD, Thomson JL, Wang YZ, Espenan G, Maloney T, Camp A, **Woltering EA**. Development of 125I-methylene blue for sentinel node lymph biopsy. J Surg Onc.: 94(4): 293-7, 2006.
120. Liu Z, Schwimer J, Liu D, Lewis J, Greenway FL, York DA, **Woltering EA**. Gallic acid is partially responsible for the antiangiogenic activities of Rubus leaf extract. Phytother Res. (9): 806-13, 2006.
121. **Woltering EA**, Hilton RS, Zolfoghary CM, Thomson J, Zietz S, Go VL, Vinik AI, Vinik E, O’Dorisio TM, Mamikunian G. Validation of serum versus plasma measurements of chromogranin A levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas. 33(3): 250-4, 2006.
122. Cundiff JD, Wang YZ, Espenan G, Maloney T, Camp A, Lazarus L, Stolier A, Brooks R, Torrance B, Stafford S, O’Leary JP, **Woltering EA**. A phase I/II trial of 125I methylene blue for one-stage sentinel lymph node biopsy. Ann Surg. 245(2): 290-6, 2007.
123. Roberts AT, Martin CK, Liu Z, Amen RJ, **Woltering EA**, Rood JC, Caruso, MK, Yu Y, Xie H, Greenway FL. The safety and efficacy of a dietary herbal supplement and gallic acid for weight loss. J. Med Food. 10(1): 184-8, 2007.
124. Greenway FL, Liu Z, Yu Y, Caruso MK, Roberts AT, Lyons J, Schwimer JE, Gupta AK, Bellanger DE, Guillot TS, **Woltering EA**. An assay to measure angiogenesis in human fat tissue. Obes Surg. 17(4): 510-5, 2007.
125. Park M, Lyons J III, Oh H, Yu Y, **Woltering EA**, Greenway F and York DA. Enterostatin inhibition of angiogenesis: possible role of pAMPK and vascular endothelial growth factor A (VEGF-A). Int J Obes 32: 922–929, 2008.
126. **Woltering EA**, Salvo VA, O’Dorisio TM, Lyons J, Li G, Zhou Y, Seward JR, Go VW, Vinik AI, Mamikunian P and Mamikunian G. Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients. Pancreas 37(1): 94-100, 2008.
127. Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, **Woltering EA**, and Anthony L. Safety and Efficacy of Radionuclide Therapy with High-Activity 111 In Pentetreotide in Patients with Progressive Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals 23(3): 292-300 2008.
128. Lyons JM III, Anthony CT, Thomson JL, and **Woltering EA**. A Novel Assay to Assess the Effectiveness of Antiangiogenic Drugs in Human Breast Cancer Ann Surg Oncol **15 (12): 3407-3410, 2008.**
129. Dong L, Schwimer J, Liu Z**,** **Woltering E**, and Greenway FL. Antiangiogenic effect of curcumin in pure versus in extract forms. Pharmaceutical Biology 46: 677-682, 2008.
130. Lyons JM III, Abergel J, Thomson J, Anthony CT, Wang YZ, Anthony L, Boudreaux JP, Strauchen J, Idrees M, Warner R, and **Woltering EA**: *In Vitro* Chemoresistance Testing in Well-Differentiated Carcinoid Tumors. Ann. of Surg. Onc. 16 (3): 649-655, 2009.
131. Wang YZ, Joseph S, Lindholm E, Lyons J, Boudreaux JP, and **Woltering EA**. Lymphatic Mapping Helps to Define Resection Margins for Midgut Carcinoids. Surgery, 146(6):993-7, 2009.
132. Lyons JM III, Schwimer JE, Anthony CT, Thomson JL, Cundiff JD, Casey DT, Maccini C, Kucera P, Wang YZ, Boudreaux JP, and **Woltering EA**: The Role of VEGF Pathways in Human Physiologic and Pathologic Angiogenesis. J. Surg. Res 159(1):517-527, 2010.
133. Wang YZ, Boudreaux JP, Dowling A, and **Woltering EA**: Percutaneous localisation of pulmonary nodules prior to video-assisted thoracoscopic surgery using methylene blue and TC-99. Eur J Cardiothorac Surg. 37(1): 237-238, 2010.
134. Vinik AI, Silva MP, **Woltering E**, Go VL, Warner R, Caplin M: Biochemical Testing for Neuroendocrine Tumors (NETs). Pancreas, 38(8):876-879, 2009. *Review Erratum In*: 39(1):117, 2010.
135. O’Dorisio TM, Krutzik SR, **Woltering EA**, Lindholm E, Joseph S, Wang YZ, Boudreaux JP, Vinik AI, Go VLW, Howe JR, Halfdanarson T, O’Dorisio MS, and Mamikunian G: Development of a Highly Sensitive and Specific Carboxy-terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior. Pancreas, 39(5):611-616, 2010.
136. Weiss SR, Tenney JM, Thompson JL, Anthony CT, Chiu ES, Friedlander PL, and **Woltering EA**: The Effect of AlloDerm® On the Initiation and Growth of Human Neovessels. Laryngoscope, 120(3):443-449, 2010.
137. Wang YZ, Boudreaux JP, Campeau RJ, and **Woltering EA**. Resolution of Pulsatile Tinnitus Following an Upper Mediastinal Lymph Node Resection. South Med J., 103(4):374-7, 2010.
138. Joseph S, Li G, Lindholm E, Zhou Y, Go VLW, Vinik AI, O’Dorisio TM, Mamikunian G, and **Woltering EA**: A Prospective Trial on the Effect of Body Mass Index and Sex on Plasma Octreotide Levels in Patients Undergoing Long-Term Octreotide LAR Therapy. Pancreas, 39 (7):964-6, 2010.
139. Vinik AI, **Woltering EA**, Warner RRP, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, and Go VLW: NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumors. Pancreas, 39(6):713-734, 2010.
140. Boudreaux JP, Klimstra DS, Hassan MM, **Woltering EA**, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, and Yao JC: The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas, 39(6):753-766, 2010.
141. Phan AT, Öberg K, Choi J, Harrison LH, Hassan MM, Strosberg JR, Krenning EP, Kocha W, **Woltering EA**, and Maples WJ: NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus). Pancreas, 39(6):784-798, 2010.
142. Vinik AI, Anthony L, Boudreaux JP, Go VLW, O'Dorisio TM, Ruszniewski P, and **Woltering EA**: Neuroendocrine Tumors: A Critical Appraisal of Management Strategies. Pancreas, 39(6):801-818, 2010.
143. Lyons J III, Anthony CT, **Woltering EA**. The role of angiogenesis in neuroendocrine tumors. Endocrinol Metab Clin N Am, 39:839-852, 2010.
144. Stalder MW, Anthony CT, **Woltering EA**. Metronomic Dosing Enhances The Anti-Angiogenic Effect of Epothilone B. J Surg Res., 169(2):247-56, 2011.
145. Joseph S, Wang YZ, Boudreaux JP, Anthony LB, Campeau R, Raines D, O’Dorisio TM, Go VLW, Vinik AI, Cundiff J, and **Woltering EA**: Neuroendocrine Tumors: Current Recommendations for Diagnosis and Surgical Management. Endocrinol Metab Clin N Am. 40(1):205-31, 2011.
146. Anthony CT, Bastidas JG, Thomson JL, LyonsIII J, Lewis JM, Schwimer JE, Casey P, Abadie J, Frey DF, Wang Y-Z, Boudreaux JP, **Woltering EA**. A Study of Pipeline Drugs in Neuroendocrine Tumors. J Gastrointest Canc DOI 10.1007/s12029-011-9286-9, 2011.
147. Mamikunian P, Ardill JES, O’Dorisio TM, Krutzik SR, Vinik AI, Go VLW, Mamikunian GM, **Woltering EA**. Validation of Neurokinin A (NKA) Assays in the United States and Europe. Pancreas, 40(7): 1000-5, 2011.
148. Wang YZ, Diebold AE, **Woltering EA**, King H, Anthony LB, Campeau R, and Boudreaux JP. Radioguided exploration to guide the surgical cytoreduction of NETs. Journal of Gastrointestinal Surgery. 16(3): 635-640, 2012.
149. Brashear J, Ryan P, Wang YZ, Anthony LB, Boudreaux JP, Joseph S, Campeau R, and **Woltering EA**. A Prospective Evaluation of the Value of Intensive Pre-visit Counseling in Patients with Neuroendocrine Tumors (NETS). The American Surgeon. 78(1):43-4, 2012.
150. Lindholm E, Lyons J, Anthony C, Boudreaux JP, Wang YZ, and **Woltering E**. Do Primary Neuroendocrine Tumors and Metastasis Have the Same Characteristics? Journal of Surgical Research. 174: 200-206, 2012.
151. Raines D, Chester M, Diebold AE, Mamikunian P, Anthony CT, Mamikunian G, and **Woltering EA**. A Prospective Evaluation of the Effect of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans. Pancreas. 41(4):508-11, 2012
152. Wang YZ, Mayhall G, Anthony LA, Campeau R, Boudreaux JP, and **Woltering EA**. Cervical and upper mediastinal lymph nodes metastasis from gastrointestinal and pancreatic neuroendocrine tumors: the true incidence and their management. Journal of the American College of Surgeons. 214:1017-1022, 2012.
153. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, Mamikunian P, Mamikunian G, and **Woltering EA**. Neurokinin A Levels Predict Survival in Patients with Well Differentiated Small Bowel Neuroendocrine Tumors. Surgery. 152(6):1172-6, 2012.
154. Tellez MR, Mamikunian G, O’Dorisio TM, Vinik AI, and Woltering EA. A Single Fasting Plasma 5-HIAA Value Correlates with 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs). Pancreas. Epub ahead of print.
155. Wang, YZ, Diebold A, Boudreaux P, Raines D, Campeau R, Anthony L, and **Woltering EA**. Surgical Treatment Options for Rectal Carcinoid Cancer: Local versus Low Radical Excision. Am Surgeon. Accepted.

**Non-refereed**

1. **Woltering EA:** Split Thickness Skin Grafting on Plantar Surface of Foot. Medilex Digest Derm 68-69, 1980.
2. **Woltering EA**: Parathyroid Carcinoma. Surg Rounds, 7:111, 1984.
3. **Woltering EA**: Fine-Needle Aspiration of Thyroid Nodules. West Jr Med, 737-738, 1987.
4. **Woltering EA**, Pommier RF, DiCioccio C, James AG, Farrar WB, Minton JP: Arm Immobilization Vs. Limited Arm Motion Following Mastectomy: Effects on Wound Complications and Shoulder Function. Surg Rounds, 2:37-40, 1988.
5. Gilchrist BF, **Woltering EA**: Ectopic Liver: An Unusual CAT Scan Abnormality. Surg Rounds 55-56, 1988.
6. **Woltering EA**: Tumor Chemosensitivity Testing: An Evolving Technique. Lab. Medicine, 21:82-84, 1990.
7. Cramer AB, Mozell EJ, O’Dorisio TM, **Woltering EA**. Functional Endocrine Tumors of the Gut: Carcinoids. Surg Rounds, 1:41-47, 1992.
8. Cramer AB, Mozell EJ, O’Dorisio TM, **Woltering EA**. Functional Endocrine Tumors of the Gut: VIPomas. Surg Rounds, 2:144-148, 1992.
9. Cramer AB, Mozell EJ, O’Dorisio TM, **Woltering EA**. Functional Endocrine Tumors of the Gut: Gastrinomas. Surg Rounds, 3:247-255, 1992.
10. Cramer AB, Mozell EJ, O’Dorisio TM, **Woltering EA**. Functional Endocrine Tumors of the Gut: Insulinomas. Surg Rounds, 4:343-348, 1992.
11. Cramer AB, Mozell EJ, O’Dorisio TM, **Woltering EA**. Functional Endocrine Tumors of the Gut: Glucagonomas and Rare Tumors. Surg Rounds, 5:447-454, 1992.
12. Billingsly K, **Woltering EA**: Ileal Lipoma Causing Intussusception. Surg Rounds 2/94; 153-155, 1994.
13. **Woltering EA**, Kessler S, Hammer E, Cook DM: A calcified parathyroid cyst: An unusual presentation of primary hyperparathyroidism. Surg Rounds 23(2):89-92, 2000.
14. Hornick CA, **Woltering EA**. Letter to the Editor: Reply to “Nuclear translocation of somatostatin analogs”. J Nuclear Med. 42(3): 530-531, 2001.
15. Lewis JM, Maxwell PJ IV, Anthony CT, Gebhardt BM, Thomson JL, Balster DA, Rothermel J, **Woltering EA**: Inhibition of Human Parathyroid Angiogenesis with a Tubulin Inhibitor. Proceedings of the XXXVIII Congress of the European Society for Surgical Research, 155-158, 2003.
16. **Woltering EA**. Letter to the Editor: Reply to “Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients”. Pancreas 37(3), 2008

**Books:**

1. O’Leary JP, **Woltering EA**, eds. Surgical Techniques, J.F. Wiley & Sons, New York, New York, 1985.
2. Heneghan JB, Redmann JG, Watson JC, Alperin-Lea RC**, Woltering EA**: Digital Image Analysis in the Development of a Human Placental Vein Angiogenesis Model (HPVAM). Germfree Life and its Ramifications, K. Hashimoto, et al (eds), XII ISG Publishing Committee, Shiozawa, Japan, 1996.
3. Heneghan JB, Hunt JD, **Woltering EA**: Establishment of a Gnotobiotic Animal Care and digital Imaging Core Facility. Germfree Life and its Ramifications. K. Hashimoto et al. (eds), XII ISG Publishing Committee, Shiozawa, Japan, 1996.
4. Vinik AI, O’Dorisio TM, Go VW, **Woltering EA**: Neuroendocrine Tumors A Comprehensive Guide to Diagnosis and Management (2nd edition). Inter Science Institute Publishers, Inglewood, CA, 2008.
5. Vinik AI, O’Dorisio TM, Go VW, **Woltering EA**: Neuroendocrine Tumors A Comprehensive Guide to Diagnosis and Management (4th edition). Inter Science Institute Publishers, Inglewood, CA, 2009.
6. **Woltering EA**, Cundiff J, and Lyons J. Principles and Practice of Surgical Oncology: A Multidisciplinary Approach to Difficult Problems. Lippincott Williams and Wilkins, Philadelphia, PA, 2009.
7. Vinik AI, **Woltering EA**, O’Dorisio TM, Go VLW, Mamikunian G: Neuroendocrine Tumors A Comprehensive Guide to Diagnosis and Management (5th edition). Inter Science Institute Publishers, Inglewood, CA, 2012.

**Book Chapters:**

1. **Woltering EA**: Repositioning Misguided Central Venous Pressure Lines. O’Leary JP, Woltering EA (eds): In: Surgical Techniques, J.F. Wiley & Sons, New York, New York, 1985.
2. **Woltering EA**: Easy Insertion of Senstaken-Blakemore Tubes. O’Leary JP, Woltering EA\*(eds): In: Surgical Techniques, J. F. Wiley & Sons, New York, New York, 1985.
3. **Woltering EA**, James AG: Methods of localizing, Identifying and Protecting the Recurrent Laryngeal Nerve. O’Leary JP, Woltering EA (eds): In: Surgical Techniques, J.F. Wiley & Sons, New York, New York, 1985.
4. Gaginella TS, O’Dorisio, TM, Mekhjian HS, O’Dorisio MS, **Woltering EA**: In: Tumors of the Gastroenteropancreatic Axis. Sandostatin in the Treatment of GEP Endocrine Tumors, Springer-Verlag, New York, New York, 1989.
5. O’Dorisio TM, Mekhjian HS, Fassler JE, O’Dorisio MS, **Woltering EA**, Gaginella TS, Gable TA, Gower WR: Somatostatin: Treatment of Gut Endocrinopathies and a Mechanism of Action. In: Thompson JC, Townsend CM (eds.) International Gastrointestinal Hormones Symposium, University of Texas Press, Galveston, Texas, 1989.
6. Fletcher WS, **Woltering EA**, Moseley HS, Bos G, Lebredo L, Brown D, Small K: Hyperthermic Isolation Limb Perfusion (HILP) in the Management of Extremity Melanoma and Sarcoma with particular reference to the dosage, pharmacokinetics and toxicity of cisplatin. In: Pediatric Oncology, Kluwer Academic Publishers, Norwell, MA, 1990.
7. **Woltering EA**, Sheppard B, Edney JA, Holder WD. The New Look of Cancer for the 1990’s. JP O’Leary (eds): In: The Physiologic Basis of Surgery. Williams & Wilkins Publishers, Baltimore, MD, 1992.
8. Fletcher WS, Pommier RF, **Woltering EA**, Mueller CR, Ash KO, Small KA: The Pharmacokinetics and Results of Dose Escalation in Cisplatin Hyperthermic Isolation Limb Perfusion (HILP): In: Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies, Kluwer Academic Publishers, Boston, 1993.
9. **Woltering EA**, O’Dorisio MS, O’Dorisio TM. The Role of Somatostatin Analogs in the Management of Cancer Patients. DeVita, (eds): In: PPO Updates, Lippincott Healthcare Publications, Philadelphia, PA, August 1995.
10. **Woltering EA**. Midgut Neuroendocrine Tumors: In Raines, DL (Ed.), Capsule Endoscopy by Case Study (pp. 57-62). American College of Gastroenterology, Bethesda, MD, 2012.

**Inventions and Patents:**

**U.S. Patent Number 5,590,656**. Issued January 7, 1997: Application of Peptide/Cell Receptor Kinetics Utilizing Radiolabeled Somatostatin Congeners in the in situ, in vivo Detection and Differentiation of Neoplastic Tissue. Inventors: O’Dorisio TM, O’Dorisio MS, Martin Jr. EW, **Woltering EA**.

**U.S. Patent Number 5,597,894**. Issued January 28, 1997: Multi-Tyrosinated Somatostatin Analogs. Inventors: Coy DH, **Woltering EA**, O’Dorisio MS, O’Dorisio TM, Murphy WA.

**U.S. Patent Number 6,180,082**. Issued January 30, 2001: Method to Enhance Tissue Accumulation of Radiolabeled Compounds. Inventors: **Woltering EA**, Espenan GD.

**U.S. Patent Number 6,465,613**. Issued October 15, 2002: Hydrophilic Somatostatin Analogs. Inventors: Coy DH, Murphy WA, **Woltering EA**, Fuselier JA, Drouant G.

**U.S. Patent Number 6,630,123**. Issued October 7, 2003: Method to Enhance Tissue Accumulation of Radiolabeled Compounds. Inventors: **Woltering EA**, Espenan GD.

**U.S. Patent Number 6,893,812**. Issued May 17, 2005: Three-Dimensional ex vivo Angiogenesis System. Inventors: **Woltering EA**, Gulec SA.

**U.S. Patent Number 7,381,400**. Issued June 3, 2008: Injection of a Radioactive Dye for Sentinel Lymph Node Identification. Inventors: **Woltering EA**.

**U.S. Patent Number 7,427,662**. Issued September 23, 2008: Inhibition of Angiogenesis and Destruction of Angiogenic Vessels by Apolipoprotein A-1 and High Density Lipoprotein. Inventors: Hornick CA, **Woltering EA**.

**U.S. Patent Number 7,709,031**. Issued May 4, 2010: Angiogenic Agents from Plant Extracts, Gallic Acid, and Derivatives. Inventors: Greenway FL, Liu Z, **Woltering EA**.

**U.S Patent Number 8,012,517**.Issued September 6, 2011: Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with Extracts of Noni Juice Morinda Citrifolia. Inventors: **Woltering EA**, Hornick CA, Myers AE.

**U.S Patent Number 8,334,000**. Issued December 18, 2012: Anti-Angiogeneic Extracts from Pomegranate. Inventors: Greenway FL, Liu Z, **Woltering EA**.

**U.S Patent Number 8,349,374**. Issued January 8, 2013: Inhibition of Angiogenesis and Destruction of Angiogenic Vessels with Extracts of Noni Juice (Morinda Citrifolia). Inventors: **Woltering EA**, Hornick CA, Myers AE.

**Applications:**

Application Number 20050255045. Applied May 13, 2004: Surgical Marking Composition and Method. Inventors: **Woltering EA**.

Application Number 20110165096. Applied August 14, 2009: Ficus Extracts Having Angiogenesis Inhibiting Activity and Methods of Isolating and Using the Same. Inventors: Liu Z, **Woltering EA**.

Application number 20110152329. Applied March 1, 2011: Application for patent: Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism. Inventors: **Woltering EA.**

**Scientific Presentations:**

1. Woltering EA, Emmott RC, Javadpour N, Brennan MF: Difference in Cell-Surface Antigens with Parathyroid Adenoma and Hyperplasia. Surgical Forum (1977)
2. Adkins RB, Bluet M, Woltering EA: Management of Penetrating Hepatic Injury: A Review of 86 Consecutive Patients. Southeastern Surgical (1983)
3. Ellison EC, Woltering EA, Hitchcock C, Nelson K, Howe B, Stephens R, Carey LC, O’Dorisio TM: The Effect of Calcium On Vasoactive Intestinal Peptide Release from an Islet Cell Tumor Associated with the Verner Morrison Syndrome. Surgical Forum (1983)
4. Woltering EA, Ellison EC, Sparks J, Hitchcock C, Nelson K, Stephens R, Carey LC, O’Dorisio TM: Effect of Calcium on Gastrin Release from Dispersed Gastrinoma Cells. Association for Academic Surgery (1983)
5. O’Dorisio TM, Woltering EA, Ellison EC, Hitchcock H, Nelson K, Hoe B, Stephens R, Carey LC: Suppression of Vasoactive Peptide Release from a Dispersed Islet Cell Tumor by Hydrocortisone. International VIP Symposium (1983)
6. Tuttle SE, Woltering EA, Sharma H: Monoclonal Antibody Localization of A, B, and H Blood Group Antigen in Human Tumors. International Academy of Pathology (1984)
7. Whiteneck JM, Woltering EA, Adkins RB: Chest Wall and Penetrating Thoracic Injuries. 51st Southeastern Surgical Congress (1984)
8. Adkins RB, Whiteneck JM, Woltering EA: Carcinoma of the Breast in the Extremes of Age. 51st Southeastern Surgical Congress (1984)
9. Woltering EA, James AG, Ferrara JJ: Prospective Evaluation of a Method for Identifying the Recurrent Laryngeal Nerve. Society of Head and Neck Surgeons (1984)
10. Tuttle SE, Woltering EA, Strobel SL: Detection of ABH Blood Group Antigens in Parotid Tumors Immunohistochemical Technique Using Monoclonal Antibodies Compared to the Specific Red Cell Adherence Test. International Academy of Pathology, IV International Congress (1984)
11. Ellison EC, O’Dorisio T, Sparks J, Woltering EA: Failure of Secretin to Stimulate Gastrin Release and Adenyl Cyclase Activity in Gastrinoma in Vitro. 5th International Symposium on Gastrointestinal Hormones (1984)
12. Woltering EA, O’Dorisio TM, Ellison EC, Minton JP, Mekhjian HS: The Response to Tolbutamide of a VIP and Somatostatin Containing ‘Nonfunctional’ Neuroendocrine Tumor. American Gastroenterology Association (1985)
13. Ellison EC, Woltering EA: Efficacy of Long-Acting Somatostatin Analogue in the Zollinger-Ellison Syndrome. American Gastroenterology Association (1985)
14. Woltering EA, O’Dorisio RM, Mekhjian HS, Ellison EC, Dyben T, Howe B, Tuttle SE, Minton JP: In Vitro Response to Tolbutamide of a Non-Expressive VIP and Somatostatin Containing Tumor. Somatostatin ‘85 (1985)
15. Woltering EA, Ellison EC, O’Dorisio TM, Sparks J, Howe B, Dyben T: Somatostatin-Like Peptides Alter Calcium but not Secretin Sensitivity of Gastrinoma Cells. Association for Academic Surgery (1985)
16. Ellison EC, Woltering EA, O’Dorisio TM, Sparks J, Mekhjian HS, Fromkies JS, Carey LC: Efficacy of Long-Acting Somatostatin Analog SMS (201-995) in the Ulcerogenic Syndrome. Gastroenterology (1985)
17. McCabe DP, O’Dwyer PJ, Sickle-Santanello BJ, Woltering EA, Issa HA, James AG: Chemoprevention of DMBA-Induced Sprague Dawley Rat Mammary Cancer by Differentiating Agents. Society of Surgical Oncology (1986)
18. Woltering EA, Ellison EC, O’Dorisio TM, Sparks J, Dyben T: Sandostatin Decreases Gastrin Release from Dispersed Gastrinoma Cells. 6th International Symposium on Gastrointestinal Hormones (1986)
19. Ellison EC, Elkammas EA, Gower WR, Woltering EA, O’Dorisio TM, Sparks J, Fabri PJ: Effect of Secretin on Gastrin Release from Gastrinoma Cells In Vitro. 6th International Symposium on Gastrointestinal Hormones (1986)
20. O’Dorisio TM, Benson GD, Woltering EA, Ellison EC, Morrison B: Control of Watery Diarrhea Syndrome in a Patient with a Vasoactive Intestinal Peptide (VIP)-Secreting Tumor Using Dexamethasone and SMS 201-995. 6th International Symposium of Gastrointestinal Hormones (1986)
21. O’Dwyer PJ, McCabe DP, Clausen K, Sickle-Santanello BJ, Klein J, Woltering EA, Martin EW, Jr.: Chemoprevention in Experimental Colon Cancer. Surgical Forum (1986)
22. Fletcher J, Woltering EA, Townsend R, Fletcher WS: Adult Onset Nesidioblastosis: Response to a Mini-Somatostatin Analogue. American College of Surgeons, Oregon Chapter (1986)
23. Pommier RF, Woltering EA, Campbell JR, Fletcher WS: Hepatic Resection for Primary and Secondary Neoplasms of the Liver. North Pacific Surgical Association (1986)
24. Ellison EC, Woltering EA, Mekhjian HS: Characterization of Somatostatin Inhibition of Gastrin Secretion From Gastrinomas in Vivo and In Vitro. Symposium on Gut Endocrinology: Clinical and Therapeutic Impact (1986)
25. Pommier RF, Woltering EA, Keenan EJ, Fletcher WS: The Mechanism of Hormone Sensitive Breast Cancer Progression on Antiestrogens: Implications for Treatment and Protocol Planning. International Society of Surgical Oncology (1987)
26. Mozell EJ, Woltering EA, O’Dorisio TM, Ellison EC, Fletcher WS: New Concepts in the Therapy of Functional Endocrine Tumors. Portland Surgical Society (1987)
27. Pommier RF, Woltering EA, Keenan EJ, Fletcher WS: The Mechanism of Hormone Sensitive Breast Cancer Progression on Anti-estrogens: Implications for Treatment and Protocol Planning. Portland Surgical Society (1987)
28. Woltering EA: Adult Onset Nesidioblastosis: Response of Serum Glucose and Plasma Peptides to a Mini-Somatostatin Analog. H. William Scott, Jr. Society (1987)
29. Pommier RF, Woltering EA, Keenan EJ, Fletcher WS: The Mechanism of Hormone Sensitive Breast Cancer Progression During Antiestrogens Therapy: Implications for Treatment and Protocol Planning. American College of Surgeons, Oregon Chapter (1987)
30. Mozell EJ, Woltering EA, O’Dorisio TM, Ellison EC, Fletcher WS, Sinclair A, Howe B: The Effect of Somatostatin Analog on Peptide Release and Tumor Growth in the Zollinger-Ellison Syndrome. American College of Surgeons, Oregon Chapter (1987)
31. Fletcher WS, Woltering EA, Keenan EJ, Pommier RF, Hartley J: The Effect of Tamoxifen After Oophorectomy on Hormone-Sensitive Breast Cancer. 32nd World Congress of Surgery (1987)
32. Pommier RF, Woltering EA, Keenan EJ, Fletcher WS: The Mechanism of Hormone Sensitive Breast Cancer Progression on Antiestrogens: Implications for Treatment and Planning. American College of Surgeons, Oregon Chapter (1987)
33. Mozell EJ, Woltering EA, O’Dorisio TM, Fletcher WS: Somatostatin Suppresses Basal and Provoked Insulin and Secondary Peptide Release in Adult Onset Nesidioblastosis. American College of Surgeons, Oregon Chapter (1987)
34. Woltering EA, O’Dorisio TM, Mozell EJ, Ellison EC, Fletcher WS: New Concepts in the Therapy of Functional Endocrine Tumors: Suppression of Primary and Secondary Peptides with Somatostatin Analog. American College of Surgeons (1987)
35. Pommier, RF, Woltering EA, Milo G, Fletcher WS: Synergistic Cytotoxicity Between Dimethyl Sulfoxide and Antineoplastics Against Ovarian Cancer In Vitro. American College of Surgeons (1987)
36. Woltering EA, Pommier RF, Milo G, Fletcher WS: Synergistic Cytotoxicity of Dimethyl Sulfoxide and Antineoplastic Combinations Against Human Tumors. North Pacific Surgical Association (1987)
37. Brown DA, Pommier RF, Woltering EA, Fletcher WS: Nonanatomic Hepatic Resection for Secondary Hepatic Tumors with Special Reference to Hemostatic Technique. Pacific Coast Surgical Assoc. (1988)
38. Williams ST, Woltering EA, O’Dorisio TM, Mozell EJ, McClung MR, Fletcher WS: Calcium Reverses Somatostatin Inhibition of Insulin Release in Insulinoma. Assoc. for Surgery of the Alimentary Tract (1988)
39. Williams ST, Woltering EA, Palmquist MA, Howe B, O’Dorisio RM, Fletcher WS: The Effect of Sandostatin on Provoked Peptide Release in Functional Endocrine Tumors of the Gastroenteropancreatic Axis. Pancreas Club (1988)
40. Williams ST, Woltering EA, O’Dorisio TM, Fletcher WS: Effect of Sandostatin on External Pancreatic Fistula Drainage. Pancreas Club (1988)
41. Pommier RF, Woltering EA, Fletcher WS: The Mechanism of Success and Failure of Megestrol Acetate Therapy in the Neuroendocrine Control of Breast Cancer. Portland Surgical Society (1988)
42. Pommier RF, Woltering EA, Fletcher WS: Synergistic Cytotoxicity of DMSO-Antineoplastic Combinations Against P388 Leukemia in CD-FI Mice. Portland Surgical Society (1988)
43. Fletcher WS, Pommier RF, Brown DA, Woltering EA: Decreased Morbidity from Non-Anatomic Hepatic Resection vs. Lobectomy for Metastatic Cancer to the Liver. Portland Surgical Society (1988)
44. Woltering EA, Williams ST, O’Dorisio TM, Fletcher WS: Clinical Response Linked to Sandostatin Suppression of Basal and Provoked Peptide Levels. Pancreas Club (1988)
45. Williams ST, Geer RJ, O’Dorisio TM, Woltering EA, Abumrad, NN, Fletcher WS: Efficacy of Somatostatin Analog SMS 201-995 in the Treatment of the Dumping Syndrome. American College of Surgeons (1988)
46. Pommier RF, Woltering EA, Fletcher WS: Synergistic Cytotoxicity of Antineoplastic-Antineoplastic Combinations Against P388 Leukemia in CD-FI Mice. Surgical Forum (1988)
47. Williams ST, Woltering EA, O’Dorisio TM, Fletcher WS: Effects of Sandostatin on Pancreatic Exocrine Function. North Pacific Surgical Association (1988)
48. Williams ST, Woltering EA, O’Dorisio TM, Fletcher WS: Effects of Sandostatin on Pancreatic Exocrine Function. The 7th International Symposium on Gastrointestinal Hormones (1988)
49. Woltering EA, Williams ST, O’Dorisio TM, Fletcher WS: Clinical Response Linked to Sandostatin Suppression of Basal and Provoked Peptide Levels. The 7th International Symposium on Gastrointestinal Hormones (1988)
50. Fletcher WS, Pommier RF, Woltering EA, Keenan EJ: The Mechanism of Hormone-Sensitive Breast Cancer Progression on Antiestrogens: Implications for Treatment and Protocol Planning. International Symposium on Endocrine Therapy (1988)
51. Pommier RF, Woltering EA, Couri D, Phillips D, Minton JP: The Pharmacokinetics of Morphine Administered via the Intravenous Hepatic, Arterial and Portal Venous Routes in Cancer Patients. North Pacific Surgical Association (1989)
52. Benson GD, O’Dorisio TM, Woltering EA, Ellison EC, Jenkins RL, Mezrich R: Management of a Patient with a Vasoactive Intestinal Peptide (VIP)-Secreting Tumor Using the Somatostatin Analog (SMS), Octreotide Acetate, Dexamethasone and Tumor Resection. International Symposium on Somatostatin (1989)
53. Woltering EA, Lebredo L, O’Dorisio TM, Williams ST, Barrie R: Treatment of Non-Endocrine Gastrointestinal Disorders by Sandostatin. International Symposium on Somatostatin (1989)
54. Lebredo L, Woltering EA, Stephens H, Mosely, Bos G, Small K, Fletcher WS: Results of Cisplatin Oregon Chapter (1989)
55. Lebredo L, Barrie R, Woltering EA: Dimethyl Sulfoxide Blocks Adriamycin Skin Ulceration. American College of Surgeons, Oregon Chapter (1989)
56. Pommier RF, Woltering EA, Couri D, Phillips D, Minton JP: Pharmacokinetics of Morphine Administered via the Intravenous, Hepatic Artery and Portal Vein Routes in Cancer Patients. American College of Surgeons, Oregon Chapter (1989)
57. Pommier RF, Woltering EA, Fletcher WS: The Mechanisms of Success and Failure of Megestrol Acetate Therapy in the Neuroendocrine Control of Breast Cancer. Pacific Coast Surgical Association (1990)
58. Fletcher WS, Lebredo L, Woltering EA, Moseley HS, Bos G, Small K: Results of Dose Escalation in Hyperthermic Isolation Limb Perfusion (HILP) with Cisplatin for Extremity Melanoma and Sarcoma: A Phase I-II Study. Society of Surgical Oncology (1990)
59. Woltering EA, O’Dorisio TM, Barrie R, Arce D, Ure T, Cramer AB, Holmes D, Robertson J, Fassler J: Somatostatin Analogues Inhibit Angiogenesis in the Chick Chorioallantoic Membrane. 8th International Symposium on Gastrointestinal Hormones (1990)
60. Walker JG, Antalis G, Mekhjian HS, Woltering EA, O’Dorisio TM: Octreotide Inhibition of Bradykinin-Stimulated Rat Colonic Chloride Secretion is Calcium Regulated. 8th International Symposium on Gastrointestinal Hormones (1990)
61. Cramer AB, Woltering EA: Treatment of Hepatic Malignancies with Hepatic Artery Infusion. American College of Surgeons, Oregon Chapter (1990)
62. Cramer AB, Woltering EA, O’Dorisio TM: Long Term Symptomatic Control of Gastrinoma with Octreotide Acetate Therapy. American College of Surgeons, Oregon Chapter (1990)
63. Woltering EA, Barrie R, O’Dorisio TM, Arce D, Ure T, Cramer AB, Holmes D, Robertson Fassler J: Somatostatin Analogues Inhibit Angiogenesis in the Chick Chorioallantoic Membrane. America College of Surgeons, Oregon Chapter (1990)
64. Walker JG, Young JJ, Mekhjian HS, Woltering EA, O’Dorisio TM: Corticosteroids inhibit VIP-induced secretion in Rat Colon In Vitro. The 8th International Symposium on Gastrointestinal Hormones (1990)
65. Mueller CR, Woltering EA, Ash KO, Hajarizadeh H, Townsend RA, Fletcher WS: Does Tripling Cisplatinum Doses in Hyperthermic Isolated Limb Perfusion Change Drug Kinetics? Society of University Surgeons (1991)
66. Mueller CR, Ure T, Barrie R, O’Dorisio TM, Woltering EA: Acute Gastric pH Changes Alter Intraluminal But Not Serum Peptide Levels. American Association of Endocrine Surgeons (1991)
67. Mueller CR, Ure T, Barrie R, O’Dorisio TM, Woltering EA: Acute Gastric pH Changes Alter Intraluminal But Not Serum Peptide Levels. Portland Surgical Society (1991)
68. Fletcher WS, Hajarizadeh H, Mueller CR, Small KS, Woltering EA: Phase I-II: Trial of Hyperthermic Isolated Limb Perfusion with Cisplatin in the Treatment of High Risk Malignant Melanoma of the Extremities. Portland Surgical Society (1991)
69. Bos GD, Croy TJ, Woltering EA, Fletcher WS: Preoperative Hyperthermic Isolation Limb Perfusion for High Grade Soft Tissue Sarcomas. Musculoskeletal Tumor Society (1991)
70. Mueller CR, Ure TM, Barrie R, O’Dorisio TM, Woltering EA: Acute Gastric pH Changes Alter Intraluminal but not Serum Peptide Levels. American College of Surgeons, Oregon Chapter (1991)
71. Hajarizadeh H, Mueller CR, Woltering EA, Small K, Fletcher WS: Phase I-II: Trial of Hyperthermic Isolated Limb Perfusion with Cisplatin in the Treatment of High Risk Malignant Melanoma of the Extremities. American College of Surgeons, Oregon Chapter (1991)
72. Hajarizadeh H, Mueller CR, Fletcher WS, Woltering EA: Effective Palliative Treatment of Metastatic Carcinoid Tumors with Intraarterial Chemotherapy/Chemoembolization Combined with Octreotide Acetate. North Pacific Surgical Association (1991)
73. Mozell EJ, Cramer AJ, Woltering EA: Long-term Efficacy of Octreotide Acetate in the Treatment of Zollinger-Ellison Syndrome. The Pacific Coast Surgical Association (1992)
74. Jones MK, Clunie DA, Szumowski J, Webber B, Woltering EA, Thurmond AS: MRI for the Evaluation of Silicone Breast Implants. American Roentgen Ray Society (1992)
75. Alcox GK, Mueller CM, Hajarizadeh H, Cramer AJ, Kurozawa D, Woltering EA: Dose-pH Relationships for Continuous Intravenous Famotidine. Portland Surgical Society (1992)
76. Mueller CM, Woltering EA, Ash KO, Hajarizadeh H, Bos G, Fletcher WS, Kessler S: Tissue Cisplatin Levels in Patients Receiving Intra-arterial Infusion and Hyperthermic Isolated Limb Perfusion. Portland Surgical Society (1992)
77. Mozell EJ, Cramer AJ, Woltering EA: Long Term Efficacy of Octreotide Acetate in the Treatment of Zollinger-Ellison Syndrome. Portland Surgical Society (1992)
78. Kurozawa D, Woltering EA, Barrie R, Alcox G, Holmes R, Hajarizadeh H and Fletcher WS: Octreotide Acetate Inhibition of Hormonally Sensitive Breast Cancer is Estrogen Dependent. Portland Surgical Society (1992)
79. Kurozawa D, Landeck S, Barrie R, Woltering EA: Somatostatin Inhibition of Angiogenesis is G Protein and Calcium Related. Portland Surgical Society (1992)
80. O’Dorisio TM, Martin EW, Wray DA, Hinkle GH, Olson J, Kafity AA, Woltering EA, Thurston MO, Mekhjian HS, Chen F, O’Dorisio MS: Clinical Application of Peptide Radio Receptor Binding Kinetics. The Endocrine Society (1992)
81. Mueller CM, Woltering EA, Ash KO, Bos G, Hajarizadeh H, Kessler S, Fletcher WS: Tissue Cisplatin Levels in Patients Receiving Intra-Arterial Infusion and Hyperthermic Isolated Limb Perfusion. American College of Surgeons, Oregon Chapter (1992)
82. Kurozawa D, Woltering EA, Barrie RJ, Alcox GK, Holmes RT, Hajarizadeh H, Fletcher WS: Octreotide Acetate Inhibition of Hormonally Sensitive Breast Cancer is Estrogen Independent. American College of Surgeons, Oregon Chapter (1992)
83. Hajarizadeh H, Lebredo L, Barrie RJ, Woltering EA: Delivery of Doxorubicin in Vitamin C or DMSO Reduces the Incidence of Skin Ulceration Following Extravasation. American College of Surgeons, Oregon Chapter (1992)
84. Jones MK, Woltering EA, Thurmond A: Localization of Nonpalpable Breast Lesions: Helping the Surgeon. American College of Surgeons, Oregon Chapter (1992)
85. Alcox GK, Mueller CM, Hajarizadeh H, Cramer AJ, Kurozawa D, Woltering EA: Dose-pH Relationships for Continuous Intravenous Famotidine. American College of Surgeons (1992)
86. O’Dorisio TM, Martin EW, Wray DA, Hinkle GH, Olson J, Kafity AA, Woltering EA, Thurston MO, Mekhjian HS, Chen F, O’Dorisio MS: Clinical Application of Peptide Radio Receptor Binding Kinetics. The 9th International Symposium on Gastrointestinal Hormones (1992)
87. Woltering EA, Landeck S, Barrie R, O’Dorisio TM: Octreotide Inhibition of Angiogenesis Is Adenylate Cyclase, C-Kinase Independent. The 9th International Symposium on Gastrointestinal Hormones (1992)
88. Woltering EA, Landeck S, Barrie R, O’Dorisio TM: Octreotide Inhibition of Angiogenesis is Adenylate Cyclase, C‑Kinase Independent. 9th International Symposium on Gastrointestinal Hormones (1992)
89. Fletcher WS, Pommier RF, Woltering EA, Mueller CR, Ash KO, Small KA: Pharmacokinetics and Results of Dose Escalation in Cisplatin Hyperthermic Isolation Limb Perfusion (HILP). Society of Surgical Oncology (1993)
90. Vetto JT, Jones MK, Pommier RF, Woltering EA: An Improved Method of Needle-Localized Biopsy of Non-Palpable Breast Lesions. Portland Surgical Society (1993)
91. Vetto JT, Jones MK, Pommier RF, Thurmond AS, Woltering EA: An Improved Method of Needle Localized Biopsy of Non-Palpable Breast Lesion. 16th Annual San Antonio Breast Cancer Symposium (1993)
92. Woltering EA, Diaco DS: Combined Treatment Modalities for Metastatic Carcinoid Tumors. New Orleans Surgical Society (1994)
93. Woltering EA, Barrie R, O’Dorisio TM, O’Dorisio MS, Nance R, Cook DM: Detection of Occult Gastrinomas Utilizing 125-I Labeled Somatuline and Intraoperative Gamma Detection. American Association of Endocrine Surgeons, Dearborn, Michigan (1994)
94. Woltering EA, Barrie R, O’Dorisio TM, O’Dorisio MS, Nance R, Cook DM: Intraoperative Gastrinoma Localization Using Radiolabeled Peptides and a Hand-held Gamma Detector. H. William Scott, Jr. Cancer Society (1994)
95. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA: Post-Receptor Signal Transduction Mechanisms Involved in Octreotide-Induced Inhibition of Angiogenesis. American Association of Endocrine Surgeons (1994)
96. Woltering EA, O’Dorisio TM, LaValle G, O’Dorisio MS, Howe B, Hill D, Minton JP: Decreases in Tissue Vasoactive Intestinal Peptide and Somatostatin are Associated with Neoplastic Transformation in the Colon. 10th International Symposium on Gastrointestinal Hormones (1994)
97. Diaco DS, Patel PC, O’Dorisio TM, Woltering EA: The Effects of Freezing/Thawing and Long Term Storage on the Degradation of Human Plasma Peptides. LSU Neuroscience Center (1994)
98. Thompson CD, O’Dorisio TM, Howe B, Hill D, Woltering EA: Calcium Reverses Somatostatin Suppression of Insulin and Glucagon Release. New Orleans Surgical Society (1994)
99. Alperin-Lea RC, Sharma C, Johnson MA, Woltering EA: Effect of Octreotide Acetate on Porcine Coronary Artery Smooth Muscle, Endothelium, and Fibroblasts. American College of Surgeons, Louisiana Chapter, and the Surgical Association of Louisiana Annual Joint Meeting (1995)
100. Traynor S, Vanderheiden S, Andersen P, Everts E, Woltering EA: Immediate and Delayed Parathyroid Gland Transplantation. The American Laryngological, Rhinological and Ontological Society (1995)
101. Sharma C, Alperin-Lea RC, Johnson MA, Burleigh BD, Woltering EA: Inhibition of Octreotide Acetate (O-A) on Proliferation of Porcine Coronary Artery Smooth Muscle, Endothelium and Fibroblasts Cells. Experimental Biology (1995)
102. Rand-Luby L, Pommier RF, Williams ST, Small KA, Woltering EA, Fletcher WS: Improved Outcome of Surgical Flaps Treated with Topical DMSO. American College of Surgeons, Oregon Chapter (1995)
103. Meyers MO, Espenan G, Drouant G, McCarthy K, Anthony L, Woltering EA: High Dose 111In-Pentetreotide Therapy of Metastatic Atypical Carcinoid Tumor. North Pacific Surgical Association (1995)
104. O’Dorisio TM, O’Dorisio MS, Chen F, Murphy WA, Woltering EA: Development of Biologically Active N-Terminally Substituted, Multi-Tyrosinated Somatostatin Analogs. 10th International Congress of Endocrinology (1996)
105. O’Dorisio MS, Chen F, Albers A, Woltering EA, O’Dorisio TM, Murphy W, Coy D: Development of a Novel Somatostatin Analogue with High Affinity for Human sst1 and sst2. 11th International Symposium on Regulatory Peptides (1996)
106. Watson JC, Redmann J, Alperin-Lea RC, Meyers MO, Woltering EA: T47D Breast Cancer Cells Enhance Initiation of In Vitro Human Angiogenesis Without Accelerating Neovessel Growth. Society of University Surgeons (1996)
107. Hajarizadeh H, Lebredo L, Barrie MS, Woltering EA: Delivery of Doxorubicin in Vitamin C or DMSO reduces the Incidence of Skin Ulceration Following Extravasation. Society of Surgical Oncology (1996)
108. Watson JC, Alperin-Lea RC, Woltering EA: Serum contains both an initiator and an inhibitor of human angiogenesis. American Association of Cancer Research (1996)
109. Watson JC, Alperin-Lea RC, Woltering EA, Gebhardt BM: The Effects of Steroid and Serum Deprivation on Growth Factor and Growth Factor Receptor Gene Transcription. Experimental Biology (1996)
110. Watson JC, Alperin-Lea, RC, Redmann JG, Gebhardt BM, Woltering EA: SST-2 Gene Expression Appears During Human Angiogenesis. 11th International Symposium on Regulatory Peptides (1996)
111. Redmann JG, Watson JC, Alperin-Lea RC, Woltering EA: Breast Cancer Initiates Human Angiogenesis But Does Not Accelerate Vessel Growth Rate. 11th International Symposium on Regulatory Peptides (1996)
112. Alperin-Lea RC, Redmann JG, Watson JC, Woltering EA: Xanthines Mediate the Anti-Proliferative Effect of Octreotide in MCF‑7 Human Mammary Carcinoma Cells. 11th International Symposium on Regulatory Peptides (1996)
113. Espenan G, Watson JC, Woltering EA, Levine EA, McCarthy K, Scott G: Development of an Optimal Nuclear Breast Imaging Protocol for Somatostatin Analogues and Comparison of Phantom Imaging to Initial clinical Results. 27th National Conference on Breast Cancer (1996)
114. Montani MC, Levine EA, Watson JC, Wray D, Alperin-Lea RC, Espenan GD, McKnight CA, O’Dorisio MS, O’Dorisio TM, Woltering EA: Intraoperative Gamma Detection of 125I-Lanreotide in Women with Primary Breast Cancer. 11th International Symposium on Regulatory Peptides (1996)
115. Woltering EA, Murphy W, O’Dorisio MS, Coy D, Drouant G, de la Claire JF, Chen F, Espenan G, O’Dorisio TM: Development of Biologically Active Multi-Iodinated Somatostatin Analogs. 11th International Symposium on Regulatory Peptides (1996)
116. Lea RC, Sharma C, Watson JC, Woltering EA: Xanthines Block Octreotide’s Inhibition of Proliferation in MCF-7 Human Breast Carcinoma Cells. American Society of Clinical Oncology (1996)
117. Thy K, Watson JC, Scott G, Neitzschman HR, Levine E, Woltering EA, Clayton J: Breast Cancer Imaging with a Radiolabeled Somatostatin (OctreoScan), Mammographic and Surgical Pathology Correlation. Radiological Society of North America (1996)
118. Montani MC, Levine EA, Watson JC, Wray D, Espenan GD, McKnight CA, O’Dorisio MS, O’Dorisio TM, Woltering EA: Intraoperative Gamma Detection of 125I-lanreotide in Women with Primary Breast Cancer. Society of Surgical Oncology (1996)
119. Watson JC, Alperin-Lea RC, Woltering EA, Gebhardt BM: The Effects of Steroid and Serum Deprivation on Growth Factor and Growth Factor Receptor Gene Transcription by Breast Cancer Cells. Experimental Biology (1996)
120. Conway MD, Sonmez M, Yang D, Woltering EA, Peyman GA: Inhibition of Corneal Angiogenesis by Octreotide Acetate (OA) in a Rabbit Micropocket Model. American Retinal vitreal Association (1996)
121. Watson JC, Alperin-Lea RC, Redmann JG, Gebhardt BM, Woltering EA: Initiation of kdr Gene Transcription is Associated with Conversion of Human Vascular Endothelium to an Angiogenic Phenotype. American College of Surgeons (1996)
122. Patel PC, Woltering EA, Maltese WA, Pellitteri PK: Squamous Cell Carcinoma-Induced Angiogenesis: A Demonstration using Cultured Cells in the Chick Chorioallantoic Membrane Model. American College of Surgeons (1996)
123. Watson JC, McCarthy KC, Espenan GD, Levine EA, McKnight CM, Meyers MO, Woltering EA: A Prospective Trial of 111In-Pentetreotide as a Staging Tool in Women with Primary Breast Cancer. Society of Surgical Oncology (1996)
124. Watson JC, Meyers MO, Alperin-Lea RC, Corona R, Woltering EA: External Beam Radiation Decreases Human Angiogenic Neovessel Growth Rates. Society of Surgical Oncology (1997)
125. Watson JC, Woltering EA: Somatostatin Receptor Imaging In Women with Intact Primary Breast Cancer Using 111In-pentetreotide. American Radium Society (1997)
126. Wang Y-Z, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Gosh P, Cooke HF: Multi-Tyrosinated Somatostatin Analog, WOC–3B, Inhibits Histamine H2 Receptor-Mediated Cyclical Chloride Secretion in the Guinea Pig Colon. AGA (1997)
127. Watson JC, Redmann J, Alperin-Lea RC, Meyers MO, Woltering EA: T47D Breast Cancer Cells Enhance Initiation of In Vitro Human Angiogenesis Without Accelerating Neovessel Growth. 10th Tripartite Meeting of the Allied University Surgeon Societies in the United Kingdom, Europe, Japan and North America (1997)
128. Meyers MO, Watson JC, McCarthy K, McKnight CM, Levine EA, Woltering EA: 111In-pentetreotide Imaging in Women with Intact Primary Breast Carcinomas: Implications for Staging and Treatment. 20th San Antonio Breast Cancer Symposium (1997)
129. Wang Y-Z, Alferes L, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Gosh P, Cooke HJ: Role of Somatostatin Receptors in Discriminating Between Mechanosensitive Release of 5-HT and PGE2 in the Initiation of Secretory Reflexes in the Guinea Pig Colon (1997)
130. Montani MC, Levine EA, Watson JC, Wray D, Espenan GD, McKnight CA, O’Dorisio MS, O’Dorisio TM, Woltering EA: Intraoperative Gamma Detection of 125I-lanreotide in Women with Primary Breast Cancer. International Symposium on Somatostatin Analogs: Basic Update and Clinical Perspectives (1997), Awarded Best Paper.
131. Meyers MO, Watson J, McCarthy K, Levine E, Espenan G, McKnight C, Woltering EA: 111In-pentetreotide Imaging in Women with Intact Primary Breast Carcinomas: Implications for Staging and Treatment. International Symposium on Somatostatin Analogs: Basic Update and Clinical Perspectives (1997)
132. O’Dorisio TM, O’Dorisio MS, Chen F, Murphy WA, Coy DH, Woltering EA: Development of Biologically Active N-Terminally Substituted, Multi-Tyrosinated Somatostatin Analogs. International Symposium on Somatostatin Analogs: Basic Update and Clinical Perspectives (1997)
133. Flattman GJ, Meyers MO, Wang YZ, Alperin-Lea RC, Woltering EA: A Novel Human Vascular Whole Organ Modification of the Boyden Chamber. Society of University Surgeons 39th Annual University Surgical Residents’ Conference (1997)
134. Meyers, MO, Woltering EA, Drouant, G, Maloney, T, Anthony, CT: Multiply Radioiodinated Somatostatin Analogs Induce Receptor-Specific Cytotoxicity. Association for Academic Surgery 31st Annual Meeting. (1997)
135. Meyers, MO, Woltering EA: Somatostatin receptor expression in human sarcoma. La. Chapter of the American College of Surgeons and Surgical Association of Louisiana Joint Annual Meeting (1998)
136. Meyers MO, Anthony LB, McCarthy K, Espenan GD, Drouant, G, Anthony CT, Woltering EA: The First North American Patient Treated with High Dose 111In-Pentetreotide Therapy for Atypical Neuroendocrine Tumors, 12th International Symposium on Regulatory Peptides. (1998)
137. Anthony, CT, Hughey, S., Woltering, EA: Caffeine Blocks Internalization of Radiolabeled Somatostatin Analogs: Implications for Scanning and in situ Radiotherapy. American Assoc. for Cancer Research (1998)
138. Meyers MO, Clasen CT, Woltering EA, Gebhardt BM, Levine EA: Somatostatin Receptor Expression in Human Sarcoma. Louisiana Chapter of the American College of surgeons and the Surgical Association of Louisiana Annual Meeting. (1998)
139. Espenan GD, McCarthy KE, Anthony LB, Woltering EA, Nelson JA: The Dosimetric Implications of Therapeutic (High Dose) 111Indium Pentetreotide in the Treatment of Somatostatin Receptor Positive Tumors. Society of Nuclear Medicine 45th Annual Meeting. (1998)
140. McCarthy KE, Espenan G, Nelson JA, Woltering EA, Neitzschman HR, Cronin M, Anthony LB: Clinical Response Correlates with Tumor Necrosis and Change in CT Density Measured by Hounsfield Units in Patients Treated with 180 mCi Doses of In‑111 Pentetreotide for Somatostatin Receptor Positive Tumors. Society of Nuclear Medicine 45th Annual Meeting. (1998)
141. McCarthy KE, Espenan G, Cronin M, Nietzschman HR, Woltering EA, Anthony LB: Visualization of Lesions is Dose Dependent Using a 180 mCi Indium-111 Pentetreotide Scan when Compared to a Standard 6 mCi Diagnostic Scan. Society of Nuclear Medicine 45th Annual Meeting. (1998)
142. McCarthy KE, Espenan G, Brooks R, Maloney L, Lemen L, Woltering EA, Anthony LB: Labeling Efficiency of Indium-111 Pentetreotide is Similar with 45, 60, and 180 mCi Doses Used for Therapy. Society of Nuclear Medicine 45th Annual Meeting. (1998)
143. Meyers MO, Anthony LB, McCarthy K, Espenan GD, Drouant, G, Anthony CT, Woltering EA: High Dose 111In-pentetreotide Therapy for Metastatic Atypical Carcinoid Tumor. Annual Scientific Assembly of the Southern Medical Association. (1998)
144. Meyers MO, Woltering EA, Clasen CT, Flattman GJ, Alperin-Lea RC, Gebhardt BM: Gene Upregulation of PDGF in Human Angiogenesis. 32nd Annual Meeting of the Association for Academic Surgery. (1998)
145. Lobrano M, Higgins J, Anthony L, Woltering EA, Neitzschman HR, McCarthy KE: CT Manifestations of Metastatic Carcinoid Syndrome with Radiopharmaceutical Receptor and Pathological Correlation. ARRS(1998)
146. Cooke HJ, Wang YZ, Alferes L, O’Dorisio TM, O’Dorisio MS, Woltering EA, Coy DH, Murphy WA, Ghosh P: Release of Paracrine Mediators Initiating Secretory Reflexes is Differentially Regulated by a Somatostatin Analog in the Guinea Pig Colon. International Symposium on Regulatory Peptides. (1998)
147. Woltering EA, Anthony LB, Espenan GD, Cronin M, McCarthy K: Renal Toxicity of High-Dose ¹¹¹In-Pentetreotide Therapy: Report of the First North American Clinical Trial. International Symposium on Regulatory Peptides. (1998)
148. McCarthy KE, Espenan GD, Cronin M, Anthony LB, Woltering EA: Visualization of Somatostatin Receptor-Positive Lesions with ¹¹¹In-Pentetreotide is Dose-Dependent. International Symposium on Regulatory Peptides. (1998)
149. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE: Efficacy of High Dose ¹¹¹In-Pentetreotide Therapy for Somatostatin Receptor Expressing Neoplasms: Report of the First North American Clinical Trial. International Symposium on Regulatory Peptides. (1998)
150. Shiflett BM, Anthony CT, Anthony LB, Woltering EA: Binding and Internalization of Radiolabeled Somatostatin Analogs. SAFMR/SSCI Student Research Award, Southern Regional Meeting, American Federation for Medical Research. (1998)
151. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Myelosuppressive Effects of ¹¹¹Indium-Pentetreotide Therapy for Somatostatin Receptor Expressing Neoplasms. American Society of Hematology Meeting. (1998)
152. Anthony CT, Hughey SH, Drouant GJ, Fuselier JA, Maloney TJ, Woltering EA: Effect of Altering Peptide to Indium Ratios on Specific Binding of 111In-Pentetreotide. Southwestern Chapter of the Society of Nuclear Medicine. (1999)
153. Drouant GJ, Hughey SH, Anthony CT, Fuselier JA, Nelson J, Gulec S, Brooks R, Hoover R, Maloney TJ, Boothe T, Woltering EA: High Dose 111In-Pentetreotide: Is There Radiolysis? Southwestern Chapter of the Society of Nuclear Medicine. (1999)
154. McCarthy KE, Lemen L, Espenan G, Woltering EA, Nelson J, Cronin MD, Maloney TJ, Anthony LB: Dose-Escalation of 111In-Pentetreotide (SomatoTher™): Toxicity and Clinical Response. Southwestern Chapter of the Society of Nuclear Medicine. (1999)
155. Lemen L, Nelson J, Espenan G, McCarthy KE, Anthony LB, Woltering EA: Predictive Power and Limitations of the Diagnostic Scan for 111In-Pentetreotide Therapy. Southwestern Chapter of the Society of Nuclear Medicine. (1999)
156. Anthony LB, Woltering EA, Espenan G, Cronin MD, Maloney TJ, McCarthy KE: High Dose 111In- Pentetreotide Therapy (SomatoTher™) Prolongs Survival in Carcinoid Syndrome. Southwestern Chapter of the Society of Nuclear Medicine. (1999)
157. Heneghan JB, Anthony CT, Gulec S, Meyers MO, Redmann JG, Fusilier J, Drouant G, Anthony LB, Woltering EA. Gnotobiotics and Anti-tumor Therapy with radiolabeled Somatostatin Analogs. ISG, Stockholm. (1999)
158. Acheson EM, Anthony CT, Gaffga CM, Woltering EA. Binding and Internalization of 125I-JIC 2D in Angiogenic Human Endothelium. National Student Research Forum (1999)
159. Meyers MO, Gagliardia AR, Flattman GJ, Wang YZ, Woltering EA. Suramin Analogues Inhibit Human Angiogenesis In Vitro. Association for Academic Surgery Annual Meeting. (1999)
160. McCarthy, K, Woltering EA, Cronin M, Espenan G, Sartor O, Maloney T, Anthony L. Targeting Somatostatin Receptor Subtype 2 with SomatoTherSM: Discordance Between Predicted and Observed Renal Radiation Exposures in a Phase II Clinical Trial. American Association for Cancer Research International Conference. (1999)
161. Anthony L, Woltering EA, Cronin M, Espenan G, Maloney T, McCarthy K, O’Dorisio T. Targeting Somatostatin Receptor Subtype 2 with SomatoTherSM: A Phase II Clinical Trial in Advanced Gastroenteropancreatic Malignancies. American Association for Cancer Research International Conference. (1999)
162. Meyers M, Clasen C, Gebhardt B, Levine E, Woltering EA: Gene Expression of VEGF in Human Sarcoma. American Society of Clinical Oncology. (2000)
163. Masse PA, Anthony CT, Wang YZ, Woltering EA. Bi-Directional Chemoattraction: The Role of Vessels and Tumors. The Society of University Surgeons Annual Meeting (Residents’ Program). (2001)
164. Francis DE, Anthony CT, Wang YZ, Woltering EA. Alpha-Interferon Inhibits Human Angiogenesis In Vitro. The Society of University Surgeons Annual Meeting (Residents’ Program). (2001)
165. Gulec SA, Gaffga CM, O’Leary JP, Woltering EA. Anti-Angiogenic Treatment with Somatostatin Receptor Mediated In Situ Radiation. Southeastern Surgical Congress Annual Meeting. (2001)
166. Woltering EA. Angiostatin®: It May Be Stock Market Gold But It Doesn’t Glitter. 29th Meeting of The H. William Scott, Jr. Society. (2001)
167. Schmidt FE, Woltering EA, Webb WR, Garcia OM, Cohen JE, Rozans MH. Sentinel Nodal Assessment in Patients with Carcinoma of the Lung. 48th Annual Meeting of the Southern Thoracic Surgical Association. (2001)
168. Lyons J, Weiss S, Anthony CT, Anthony J, Cormier J, Delacroix S, Lewis J, Maxwell IV PJ, Woltering EA. Development of Renal Protective Schemes for Use with High-Dose 111In-pentetreotide Radiotherapy. Joint Annual Meeting: LA Chapter-American College of Surgeons and Surgical Association of Louisiana. (2002)
169. Weiss S, Lyons, J, Anthony CT, Woltering EA. The Effect of Small, Positively Charged Molecules on the Specific Binding of 111In-pentetreotide to sst 2 Receptor-Expressing IMR-32 Cells. Joint Annual Meeting: LA Chapter-American College of Surgeons and Surgical Association of Louisiana. (2002)
170. Gulec SA, Eckert M, Woltering EA. Gamma Probe-Guided Lymph Node Sampling (“Gamma Picking”) in Differentiated Thyroid Carcinoma. Southeastern Surgical Congress. (2002)
171. Maxwell IV PJ, Lewis JM, Watson JC, Meyers MO, Espenan TD, Anthony CT, Woltering EA. External Beam Radiation Does Not Inhibit the Human “Angiogenic Switch”. Society of University Surgeons. (2002)
172. Lewis JM, Maxwell IV PJ, Anthony CT, Hornick CA, Myers AE, Woltering EA. Noni Effectively Inhibits Human Angiogenesis. Southeastern Surgical Congress. (2002)
173. Lyons J, Weiss S, Anthony CT, Anthony J, Cormier J, Delacroix S, Lewis J, Maxwell IV PJ, Woltering EA. Development of Renal Protective Schemes for Use with High-Dose 111In-pentetreotide Radiotherapy. National Student Research Forum. (2002)
174. Weiss S, Lyons, J, Anthony CT, Woltering EA. The Effect of Small, Positively Charged Molecules on the Specific Binding of 111In-pentetreotide to sst 2 Receptor-Expressing IMR-32 Cells. National Student Research Forum. (2002)
175. Woltering EA. Antiangiogenesis as a Mechanism for the Antitumor Effects of Octreotide. Published: Supplement to Oncology: The Role of Octreotide in Cancer and Therapy-Related Complications. (2002)
176. Gulec et al. Antiangiogenic and Antitumor Effects of Auger-Emitting Radiolabeled Somatostatin Analogs. 49th Annual Meeting, Society of Nuclear Medicine. (2002)
177. McCarthy K, Powers A, Lemen L, Nelson J, Cronin M, Espenan G, Woltering E, O’Dorisio T, Anthony L. Dosimetry of 111Indium-pentetreotide Predicts Responses to High Dose Radiotherapy with Somatostatin Analogs in Patients with Gastroenteropancreatic Tumors. AACR (2002)
178. Woltering EA. Sst 2 Overexpression in Human Angiogenic Vessels: A Unique Target for Antitumor Therapy. 15th IRIST Meeting. (2002)
179. Woltering EA, Lewis JM, Maxwell IV PJ, Frey DJ, Wang YZ, Rothermel J, Anthony CT, Balster DA, O’Leary JP, Harrison LH. Development of a Novel In Vitro Human Tumor-Based Angiogenesis Assay to Evaluate the Effect of Antiangiogenic Drugs on Individual Patient Tumors. Southern Surgical Association (2002)
180. Maxwell IV PJ, Lewis JM, Anthony CT, Watson JC, Meyers MO, Espenan TD, Espenan GD, Wang YZ, Woltering EA. External Beam Radiation Therapy Does Not Inhibit the Human “Angiogenic Switch” But Decreases Endothelial Cell Growth and Angiogenic Vessel Development. Society of Surgical Oncology. (2002)
181. Lewis JM, Anthony CT, Rothermel J, Woltering EA. Inhibition of Human Parathyroid-Derived Angiogenesis with Epothilone B, a Tubulin Inhibitor. H. William Scott, Jr. Society. (2003)
182. Conway MD, Lewis JM, Peyman GA, Bezerra Y, Anthony CT, Woltering EA. A Novel Bovine Eye Angiogenesis Assay. The Association for Research in Vision and Ophthalmology (ARVO). (2003)
183. Lewis JM, Maxwell IV PJ, Anthony CT, Rothermel J, Woltering EA. Inhibition of Human Parathyroid-Derived Angiogenesis with Epothilone B, A Tubulin Inhibitor. XXXVIII Congress of the European Society for Surgical Research. (2003)
184. Peyman GA, Conway MD, Bezerra Y, Lewis J, Anthony C, Woltering E. ARMD Management Challenges. Proceedings of the 14th Congress of the European Society of Ophthalmology, Madrid. (2003)
185. Lewis JM, Grafton LH, Maxwell IV, PJ, Martin LF, Nesbitt LT, Wang Y-Z, Woltering EA. Development of an Architecturally-Intact Human Skin-Based Angiogenesis Model. ACS Surg Forum. (2003)
186. Woltering EA, Lyons J. Investigations into human angiogenesis: the role of VEGF pathways in physiologic and pathologic angiogenesis. Louisiana Chapter American College of Surgeons and Surgical Association of Louisiana. (2008)
187. Woltering EA, Lyons J. Biochemical Markers Interpreting Laboratory Observations to Clinic Use. NANETS Symposium. (2008)
188. Woltering EA, Lyons J. In Vitro Chemoresistance Testing in Well Differentiated Carcinoid Tumors. Society of Surgical Oncology. (2008)
189. Lyons, IIIJM, AbergelJ, ThomsonJL, WangYZ, AnthonyLB, BoudreauxJP, StrauchenJ, IdreesM, Warner RRP, Woltering EA: *In vitro* chemoresistance testing in well differentiated carcinoid tumors. Society of Surgical Oncology (2008)
190. Lyons III, JM, Lindholm E, AnthonyLB, WangYZ, WolteringEA, BoudreauxJP. Metastatic carcinoid causing encasement of the mesenteric vasculature should not preclude cytoreduction. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2008)
191. Lyons III, JM, Lindholm E, AnthonyLB, BoudreauxJP, WolteringEA, WangYZ. Application of Sentinel Lymph Node Mapping in Abdominal Carcinoid Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2008)
192. Lyons JM, Abergel J, WangYZ, AnthonyLB, BoudreauxJP, Warner RRP, Woltering EA: In-Vitro Analysis of Chemo-resistance in Patients with “Typical” and “Atypical” Carcinoid Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2008)
193. Wang YZ, Diebold AE, Woltering EA, King H, Anthony LB, Campeau R, and Boudreaux JP. Radioguided Exploration to Guide the Surgical Cytoreduction of NETs. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2010)
194. Diebold A, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, Woltering EA: Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2011)
195. Woltering EA, Diebold AE, Wang YZ, Anthony LB, Boudreaux JP, Uhlhorn AP, Ryan P, Burns LAK, Frey D, Raines D, Majoria R, and Campeau R. Treatment of Small Bowel Neuroendocrine Tumors (NETs) in a Multidisciplinary Specialty Center Increases Survival. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2011)
196. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering E. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2011)
197. Wang YZ, Mayhall G, Anthony L, Campeau R, Boudreaux JP, and Woltering E. Cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors: The true incidence and their management. American College of Surgeons Annual Meeting (2011)
198. Diebold A, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, Woltering EA: Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors. American Association of Endocrine Surgeons Annual Meeting. (2012)
199. Woltering EA, Diebold AE, Wang YZ, Anthony LB, Boudreaux JP, Uhlhorn AP, Ryan P, Burns LAK, Frey D, Raines D, Majoria R, and Campeau R. Treatment of Small Bowel Neuroendocrine Tumors (NETs) in a Multidisciplinary Specialty Center Increases Survival. Louisiana American College of Surgeons Annual Meeting. (2012)
200. Wang YZ, Diebold AE, Boudreaux JP, Raines D, Campeau R, Anthony L, and Woltering EA. Surgical treatment options for rectal carcinoid cancer. SAGES Annual Meeting. (2012)
201. Hall M, Milosavljevic T, Casey P, Anthony C, and Wotlering E. Somatostatin Receptor Subtupes 1-5 Gene Expression Differs in Multiple Sites in the Same Individual. SSO Annual Meeting. (2012)
202. Hall M, Milosavljevic T, Casey P, Anthony C, and Wotlering E. Somatostatin Receptor Subtupes 1-5 Gene Expression Differs in Multiple Sites in the Same Individual. ASCO GI Symposium. (2012)
203. Wang YZ, Diebold A, Boudreaux P, Campeau R, Anthony L and Woltering E. Ovarian Metastasis from Midgut Neuroendocrine Tumors: Incidence, Clinical Implications and Management Options. American College of Surgeons Annual Meeting. (2012)
204. Wang YZ, Diebold A, Boudreaux P, Raines D, Anthony L, Woltering E. Surgical Treatment Options for Rectal Carcinoid Cancer: Trans-Anal Excision versus Low Anterior Resection with Total Mesorectal Excision. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2012)
205. Diebold AE, Tellez MR, Mamikunian G, Go VLW, O’Dorisio TM, Vinik AI, Woltering EA. A Single Fasting Plasma 5-HIAA Value Correlates with 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs). North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2012)
206. Boudreaux JP, Diebold AE, Wang YZ, Woltering EA. Resection of Liver Metastasis in Midgut Neuroendocrine Tumors Affects 10-Year Survival. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2012)
207. Boudreaux JP, Wang YZ, Diebold AE, Woltering EA. Lymph Node Positivity in Patients with Small T1 and T2 Midgut Neuroendocrine Tumors. North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (2012)
208. Harkrider WW, Diebold AE, Maloney T, Espenan G, Wang YZ, Stafford SJ, Camp A, Frey D, Chappuis C, Woltering EA. An Extended Phase II Trial of 125-I Methylene Blue for Sentinel Lymph Node Identification in Women with Breast Cancer. Southern Surgical Association Annual Meeting. (2012)

**Invited Presentations and Seminars:**

1. Vanderbilt University School of Medicine (H. William Scott, Jr. Society): ABO Antigens in Benign and Malignant Parotid Tumors. (1983)
2. Vanderbilt University School of Medicine (H. William Scott, Jr. Society): Synergistic Cytotoxicity of Dimethyl Sulfoxide and Antineoplastic Agents in the Clonogenic Assay. (1984)
3. 6th Annual Cancer Conference for Health Professional Students: Current State of the Art for Diagnosis and Treatment of Colon Cancer. (1985)
4. Association for Academic Surgery: Somatostatin-Like Peptides Alter Calcium but not Secretin Sensitivity of Dispersed Gastrinoma Cells. (1986)
5. Oregon Association of Nurse Practitioners: Breast Cancer 1987: The State of the Art in Diagnosis and Therapy. (1987)
6. Vanderbilt University (H. William Scott, Jr. Society): Adult Onset Nesidioblastosis: Response of Serum Glucose and Plasma Peptides to a Mini Somatostatin Analog. (1987)
7. Sacramento Gut Club: Functional Endocrine Tumors: An Experiment in Nature. (1987)
8. Texas Technical Health Sciences University: Effects of Sandostatin on Primary and Secondary Gut Peptides. (1987)
9. Trippler Army Medical Center: Somatostatin Analog: A New Concept in the Therapy of Functional Endocrine Tumors of the Gut. (1987)
10. Maddigan Army Medical Center: New Uses of SMS 201-995, a Mini Somatostatin Analog. (1987)
11. University of Utah: Sandostatin, a New Therapy for Endocrine Tumors. (1987)
12. Stanford University: Functional Endocrine Tumors—Primary and Secondary Peptides Relate to Clinical Syndromes. (1987)
13. University of Iowa: Functional Endocrine Tumors and Their Relationship to Abnormal Peptide Levels (1987)
14. Oregon Health Sciences University (Continuing Medical Education): Health Issues for the Mid-Life Woman: Breast Cancer (1987)
15. Oregon Health Sciences University (G.I. Surgical Conference): Use of Somatostatin Analogue in Functional Endocrine Tumors of the Gut. (1988)
16. Baylor University Medical Center (Surgical Grand Rounds): Control of Functional Endocrine Tumor Symptoms with Synthetic Somatostatin. (1988)
17. University of California at Irvine, New Concepts in the Therapy of Gut Endocrine Tumors. (1988)
18. Orange County. Gastroenterological Society: Analysis of Gastrinoma Response to Calcium, Secretin and SMS (1988)
19. Oregon Health Sciences University (Grand Rounds): Peptide Assays and Somatostatin Therapy in the Diagnosis and Management of Functional Endocrine Tumors. (1988)
20. Oregon Health Sciences University (Prime Time for Women): One in Ten Women with Breast Cancer—What are my Chances? (1988)
21. University of Utah Snowbird Conference: Somatostatin: Its Use in Modern Medicine. (1988)
22. Portland Adventist Medical Center (Weekly Cancer Conference): Functional Endocrine Tumors. (1988)
23. Oregon Health Sciences University (General Surgery Postgraduate Course): Modern Therapy of APUDomas. (1988)
24. Pittsburgh Gut Club: Uses of Sandostatin—A New Mini Somatostatin Analog. (1988)
25. Portland Academy of Medicine: Sandostatin—A New Era of Peptide Therapy. (1988)
26. University of South Carolina: Modern Therapy of Functional Endocrine Tumors. (1988)
27. Vanderbilt University: Suppression of Peptide Release From Functional Endocrine Tumors: New Uses of a Novel Somatostatin Analog. (1988)
28. Loma Linda University: The Effects of Somatostatin Analogue on Neuroendocrine Peptide Release in Pancreatic Tumors and The Role of Somatostatin Analogue in the Management of Dumping Syndrome and GI Fistulas. (1988)
29. University of Southern California/Los Angeles County Hospital (GI Conference): Functional Endocrine Tumors of the Gut: An Evolving Role of Non-Surgical Therapy. (1988)
30. University of California at Los Angeles (Wadsworth VA Surgical Grand Rounds): Sandostatin, A New Synthetic Somatostatin - Future Uses and Current Indications. (1988)
31. Oklahoma City Gut Club (1988)
32. University of Arizona (Surgical Grand Rounds). (1988)
33. Sandoz Pharmaceuticals, Inc. (Sandostatin® Launch Meeting): Sandostatin: New Perspectives, Horizons and Markets. (1988)
34. The 7th International Symposium on Gastrointestinal Hormones: Effects of Sandostatin on Pancreatic Exocrine Function. (1988)
35. University of California at San Francisco (Post Graduate Course on Peptidomimemic Therapy): Use of Somatostatin in Non-Carcinoid Gut Endocrine Tumors. (1988)
36. Medical University of South Carolina: Current and Future Uses of Sandostatin. (1989)
37. Georgia Baptist Medical Center: New Concepts in the Therapy of Endocrine Tumors. (1989)
38. VA Medical Center: Sandostatin, A New Somatostatin Analog. (1989)
39. University of Tennessee Memorial Hospital: Sandostatin, A New Somatostatin Analog. (1989)
40. St. Joseph’s Hospital: Current and Future Uses of Sandostatin. (1989)
41. Oregon Health Sciences University (Post Graduate Course): Somatostatin in GI Disorders. (1989)
42. University of Pittsburgh: Gastrointestinal Endocrine Tumors. (1989)
43. National Institutes of Health (Workshop): Sandostatin and Angiogenesis. (1989)
44. American Cancer Society (31st Annual Science Writer’s Seminar): Octreotide Acetate Controls Peptide Release from Functional Endocrine Tumors of the Gut. (1989)
45. University of Arkansas for Medical Sciences: Neuroendocrine Disorders of the Gastroenteropancreatic System: Clinical Applications of Sandostatin (Octreotide Acetate). (1989)
46. University of Texas Health Science Center: Sandostatin® in Surgical Applications. (1989)
47. M. D. Anderson Cancer Center: Sandostatin in Surgical Applications. (1989)
48. Methodist Hospital: Sandostatin in Surgical Applications. (1989)
49. Jewish Hospital at Washington University Medical Center: The Application of Somatostatin in the Management of Surgical Patients. (1989)
50. Presbyterian Hospital of San Francisco: Current and Future Uses of Sandostatin. (1989)
51. Stanford University (Surgical Grand Rounds): Current and Future Uses of Sandostatin®. (1989)
52. International Symposium on Somatostatin: Treatment of Neuroendocrine Gastrointestinal Disorders by Sandostatin. (1989)
53. Milwaukee County Medical Complex: Sandostatin: The Off-Switch for Gut Endocrine Tumors. (1989)
54. Marshfield Clinic of Wisconsin: What’s New in the Therapy of Gastrointestinal Disorders: Octreotide Acetate. (1989)
55. University of Pittsburgh School of Medicine: (Surgical Grand Rounds): Endocrine and Non-Endocrine Uses of Octreotide Acetate. (1989)
56. Cedars–Sinai Medical Center of Los Angeles: Surgical Uses of Somatostatin Analog. (1989)
57. University of California at Los Angeles Medical School: Surgical Uses of Somatostatin Analog. (1989)
58. St. Vincent’s Hospital of San Francisco: Surgical Uses of Somatostatin Analog. (1989)
59. 13th Annual Pacific Northwest Review of Obstetrics and Gynecology: Breast Disease: An Oncologist’s Perspective. (1989)
60. Children’s Hospital of Kansas City: Endocrine and Non-Endocrine Uses of Somatostatin Analogs (1989)
61. Truman Medical Center of Kansas City: Update on Use of Somatostatin Analogs in Oncologic Disorders (1989)
62. T2 Meeting: The Uses of Sandostatin in the Treatment of Gastrointestinal Malignancies. (1990)
63. American Society of Parenteral and Enteral Nutrition: Role of Sandostatin in Gastroenteropancreatic Disease & Future of Sandostatin. (1990)
64. University of Colorado Health Sciences Center: The Endocrine & Nonendocrine Applications of Octreotide Acetate. (1990)
65. Southwestern Medical Center: Advances in the Therapy of Functional Endocrine Tumors of the Gut (1990)
66. Oak Knoll Naval Hospital: Current and Future Uses of Sandostatin. (1990)
67. Children’s Hospital of San Francisco: Current and Future Uses of Sandostatin. (1990)
68. Washington Hospital of Fremont: Current and Future Uses of Sandostatin. (1990)
69. The Chinese University of Hong Kong: Treatment of Post Gastrectomy Dumping Syndrome in Patients With Gastric Cancer (1990)
70. The Chinese University of Hong Kong: Treatment of Zollinger-Ellison Syndrome. (1990)
71. The Chinese University of Hong Kong: Treatment of Pancreatic Fistula. (1990)
72. University of Wisconsin: Sandostatin; A New Therapy for Endocrine Tumors of the Gut. (1991)
73. The Cancer Institute at Washington Hospital Center: Somatostatin and Its Applications for General Surgery. (1991)
74. Oregon Health Sciences University (General Surgery Postgraduate Course): Medical Treatment of APUDomas. (1991)
75. Pacific Coast Obstetrical & Gynecological Society: Estrogen Replacement Therapy and Breast Cancer (1991)
76. Kansas City Surgical Society: Somatostatin Analogues: Clinical Uses Today and Tomorrow. (1991)
77. University of California at Davis Cancer Center: Sandostatin and its uses in the Surgical Patient: New and Emerging Issues. (1991)
78. University of Kansas Medical Center: The Role of Gut Peptides in Oncologic Disorders. (1991)
79. The Ohio State University School of Medicine (Endocrinology Update Course): Non-Carcinoid Endocrine Cancers of the Gut. (1991)
80. University of Washington Medical Center (Medicine Grand Rounds): New Concepts in the Management of Gut Endocrine Tumors. (1991)
81. Sinai Samaritan Hospital (Medicine Grand Rounds): Somatostatin: The Pivotal Peptide. (1992)
82. Planned Parenthood of the Columbia/Willamette Valley: Breast Conditions. (1992)
83. Oregon Health Sciences University (General Surgery Post Graduate Course): Non-Operative Treatment of Liver Metastases. (1992)
84. Michael Reese Hospital: Surgical Uses of Somatostatin Analogues. (1992)
85. Central Coast Medical Update: Breast Cancer: Changing Perspectives. (1992)
86. Louisiana State University Medical Center: Advances in Peptide Therapy. (1992)
87. Sandoz Pharmaceuticals Corp.: Therapeutic Modalities for Gastrointestinal-Endocrine Tumors. (1993)
88. University of Washington: Post Surgical Complications and their Management. (1993)
89. American Cancer Society: New Concepts in the Therapy of Gut Endocrine Tumors. (1993)
90. Planned Parenthood of Portland: Breast Masses, Fibrocystic Disease & Tamoxifen: New Approaches. (1993)
91. The Ohio State University (Medical Grand Rounds): Octreotide Acetate: Dosing and Efficacy. (1993)
92. American Cancer Society (Oncology Consult Program): Somatostatin’s Role in the Control of Tumor Growth and Angiogenesis. (1993)
93. American Cancer Society (Oncology Consult Program): New Concepts in the Therapy of Gut Endocrine Tumors. (1993)
94. American Cancer Society (Oncology Consult Program) Loma Linda, CA: Changing Perspectives in the Management of Breast Cancer. (1993)
95. University of Southern California (Oncology Grand Rounds): Therapeutic Modalities for GI Endocrine Tumors. (1993)
96. University of California at Los Angeles (Clinical Endocrinology Conference): Update on diagnosis and Management of G.I. endocrine Tumors. (1993)
97. Medical College of Wisconsin (Hematology/Oncology Division Conference): Islet Cell Tumors (1993)
98. 7th Congress of the Asian Federation of Endocrine Societies: Hormone Therapy in Oncology. (1993)
99. Endocrine & Metabolic Society of Singapore: Hormones in Oncology. (1993)
100. Endocrine Society of Malaysia: Hormones in Oncology. (1993)
101. Southern Baptist Hospital of New Orleans (Grand Rounds): Breast Cancer: Controversy and Heresy (1993)
102. Southern Baptist Hospital of New Orleans (Grand Rounds): Somatostatin-like Peptides Inhibit Angiogenesis and Tumor Growth. (1993)
103. The Medical Center of East New Orleans (Monthly Continuing Medical Education): Non-operative Management of Liver Tumors. (1993)
104. Tulane University Medical Center (Surgical Grand Rounds): Somatostatin: Effects on Tumor Growth and Angiogenesis. (1993)
105. Endocrine & Metabolic Society of Singapore: Hormones in Oncology. (1993)
106. 7th Congress of ASEAN Federation of Endocrine Societies: Hormone Therapy in Oncology. (1993)
107. The Internal Medicine Group: Non-Operative Management of Liver Tumors. (1993)
108. Touro Infirmary: New Concepts in the Management of Functional Endocrine Tumors. (1993)
109. Ochsner Clinic (Medical Grand Rounds): Somatostatin-like Peptides Inhibit Tumor Growth and Angiogenesis. (1993)
110. Ochsner Medical Center (Fourth Endocrinology Update): The Therapy of Gut Endocrine Tumors. (1994)
111. Sylvester Comprehensive Cancer Center: Angiogenesis. (1994)
112. Sylvester Comprehensive Cancer Center: Breast Cancer: Controversy and Heresy. (1994)
113. University of Florida: Surgical Uses of Somatostatin and its Analogs. (1994)
114. Sandoz Research Institute: Peptides and Angiogenesis: A Look at the Future. (1994)
115. Louisiana State University Medical Center (Neuroscience Center of Excellence): Things I’ve Learned From an Egg: Somatostatin-induced Inhibition of Angiogenesis. (1994)
116. Tulane University Medical Center/Louisiana State University Medical Center (Combined Grand Rounds): Pink Zebras with Purple Polka Dots . . . (1994)
117. Southern Baptist Hospital: Somatostatin Like Peptides Inhibit Angiogenesis and Tumor Growth. (1994)
118. Louisiana State University Medical Center (American Program Directors in Surgery’s Surgical Basic Science Course): Pancreatic-Biliary Peptides. (1994)
119. Louisiana State University Medical Center (The Stanley S. Scott Cancer Center): The Role Somatostatin as a Biological Response Modifier: Angiogenesis and Tumor Growth/Inhibition. (1994)
120. Cedars-Sinai Medical Center of Los Angeles: Treatment of Pancreatic GI and Complex Fistulas with Octreotide Acetate. (1994)
121. Cedars-Sinai Medical Center, Los Angeles, CA: Management of Perioperative Complications in GI Surgery. (1994)
122. The Lahey Clinic: Somatostatin Inhibition of Tumor Growth and Angiogenesis: A New Role for an Old Friend. (1994)
123. Brown University (Rhode Island Oncology Group): Somatostatin Inhibition of Tumor Growth and Angiogenesis: A New Role for an Old Friend. (1994)
124. Dana Farber Cancer Institute: Somatostatin Inhibition of Tumor Growth and Angiogenesis: A New Role for an Old Friend. (1994)
125. University of Massachusetts, School of Medicine: Somatostatin Inhibition of Tumor Growth and Angiogenesis: A New Role for an Old Friend. (1994)
126. Louisiana State University Medical Center (Pulmonary Division): New Ideas in the Detection of Cancer (1994)
127. St. Luke’s Cancer Center of Milwaukee (Schroeder Fellows Program in Clinical Oncology): Use of Somatostatin and its Analogs in Breast Cancer. (1994)
128. University of Michigan Comprehensive Cancer Center: The Role of Somatostatin Analogs in Tumor Growth and Angiogenesis. (1994)
129. Sandoz Pharmaceuticals, Ltd.: Somatostatin and Its Role In Angiogenesis and Inhibition of Tumor Growth. (1995)
130. Alton Ochsner Medical Foundation (5th Annual Jazz Festival Endocrine Update): Diagnostic and Therapeutic Applications of Somatostatin Analogs in Endocrine Tumors. (1995)
131. Louisiana State University Medical Center (American Program Directors in Surgery - Surgical Basic Science Course): GI Peptides. (1995)
132. University of Rochester Medical Center: Somatostatin Inhibitor of Tumor Growth. (1995)
133. University of Rochester Medical Center: Somatostatin Inhibitor of Tumor Growth and Angiogenesis—A New Role for an Old Peptide. (1995)
134. Cancer Therapy and Research Center: Effects of Octreotide on Angiogenesis and Tumor Growth (1995)
135. The Ohio State University: Development of Multi-tyrosinated/Multi-Halogenated Somatostatin Analogs for in situ Radiation Therapy: A Case Report. (1995)
136. Cambridge Healthtech Institute (Angiogenesis Antagonists Meeting): Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1995)
137. Association of Program Directors in Surgery 8th Annual Basic Science Course: GI Peptides (1995)
138. East Jefferson Medical Center (Bosom Buddies Breast Cancer Support Group): Breast Cancer (1996)
139. University of Washington (Oncology Grand Rounds): Somatostatin Analogs Inhibit Angiogenesis and Tumor Growth. (1996)
140. Memorial Medical Center: The Truth About Conservation Surgery in Breast Cancer. (1996)
141. Southeastern Surgical Congress (Comprehensive Clinical Review in General Surgery): Peptides and Their Actions. (1996)
142. American Program Directors in Surgery (Surgical Basic Science Course): GI Peptides. (1996)
143. Southeastern Surgical Congress (Comprehensive Clinical Review in General Surgery): GI Peptides. (1996)
144. George Washington University (Pharmacology, Medicine, Hematology/Oncology, Molecular and Cellular Oncology Grand Rounds): Somatostatin Analogs: A New Class of Biologic Modifiers that Inhibit Tumor Growth and Angiogenesis. (1996)
145. Association of Program Directors in Surgery (Annual Basic Science Course): GI Peptides. (1996)
146. Rush-Presbyterian–St. Luke’s Medical Center/Rush University: A Surgeon’s Use of Radiolabeled Peptides. (1996)
147. University of Kansas Medical Center (Surgery Grand Rounds): Tumor Angiogenesis. (1996)
148. The Stanley S. Scott Cancer Center (Oncology Grand Rounds): Development of Radiolabeled Peptides – The TILT System. (1996)
149. 38th Annual Meeting of the Southeastern Chapter of the Society of Nuclear Medicine: Somatostatin Receptor Technology: Tumor Imaging/Localization/ Treatment. (1997)
150. Medical College of Georgia (Grand Rounds): Somatostatin Analogs Inhibit Angiogenesis and Tumor Growth. (1997)
151. Memorial Medical Center (Grand Rounds): Somatostatin Inhibition of Angiogenesis & Tumor Growth. (1997)
152. Association of Program Directors in Surgery’s 8th Annual Basic Science Course: GI Peptides. (1997)
153. Southeastern Surgical Congress’s Comprehensive Clinical Review in General Surgery: Peptides and Their Actions. (1997)
154. Bayamon Regional Hospital, University Hospital Ramon Ruiz Arnau, Puerto Rico (Internal Medicine Grand Rounds): Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1997)
155. Veterans Administration Hospital, Puerto Rico (Grand Rounds): Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1997)
156. Fourth International Symposium on Neuroendocrine Tumors; Molecular genetics, growth regulating and imaging (Ivalo, Finland): Somatostatin and Angiogenesis. (1997)
157. San Juan Municipal Hospital, Puerto Rico (Hem/Onc. Grand Rounds): Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1997)
158. Surgeons Travel Club: Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1997)
159. Emory University School of Medicine (Hematology/Oncology Grand Rounds): Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1997)
160. V.A. Puget Sound Medical Center (Oncology and Surgery Grand Rounds): Somatostatin Inhibition of Angiogenesis and Tumor Growth. (1998)
161. City of Hope National Medical Center, Duarte, CA. (1998)
162. Cedar-Sinai Hospital, Los Angeles, CA: Gut Peptides and Their Clinical Use. (1998)
163. Medical Center of South Carolina (Medical Grand Rounds): Use of Somatostatin Analogues to Control Tumor Growth and Angiogenesis. (1998)
164. Medical Center of South Carolina (Research Seminar): Novel Applications of Somatostatin Analogues: Intraoperative Tumor Localization, Scintigraphy, and In Situ Radiotherapy. (1998)
165. Roger Williams Medical Center, Providence, RI (Whitmarsh Lecture): Novel Inhibitors of Angiogenesis: A Surgeon’s Perspective. (1998)
166. Association for Academic Surgery (32nd Annual Meeting): Gene Upregulation of PDGF in Human Angiogenesis (1998)
167. Louisiana State University Obesity Research Program Seminar: Peptide Binding and Internalization (1998)
168. Beth Israel Tumor Board, Newark, NJ: Use of Somatostatin Analogues to Control Tumor Growth and Angiogenesis. (1999)
169. Southeastern Surgical Congress, Tampa, FL (67th Annual Meeting): TILTS: Tumor Imaging Localization and Therapy System. (1999)
170. Kansas Cancer Institute, Kansas City, KS: Somatostatin Analogs—Effects on Tumor Growth and Angiogenesis. (1999)
171. U.S. Department of Energy, Washington, DC: (Accomplishments with Medical Isotopes): 111In-pentetreotide Tumor Therapy. (1999)
172. Jackson Memorial Hospital, University of Miami, FL (Department of GI): Carcinoid Syndrome. (1999)
173. Jackson Memorial Hospital, University of Miami, FL (Department of Hem/Onc): Somatostatin Analogs—Effects on Tumor Growth and Angiogenesis. (1999)
174. University Medical Center, San Juan, Puerto Rico: Carcinoid Tumors. (1999)
175. University of Puerto Rico, San Juan, PR: Somatostatin Analogs—Effects on Tumor Growth and Angiogenesis.(1999)
176. Society of Nuclear Medicine Annual Meeting, Los Angeles, CA: Therapeutic 111In pentetreotide: A New Standard of Care. (1999)
177. Idaho Chapter - American College of Surgeons, Sun Valley, ID: Carcinoid Tumors and Somatostatin (1999)
178. Carcinoid Research Conference, Chicago, IL: Role of Somatostatin and Analogs. (1999)
179. Association of Program Directors in Surgery Tenth Annual Surgical Basic Science Course, Baltimore, MD: GI Hormones. (1999)
180. St. Louis University Medical School’s Hematology/Oncology and Surgery Department Tumor/General Surgery Grand Rounds Conference, St. Louis, MO: TILTS: Tumor Imaging Localization and Therapy System. (1999)
181. Department of Internal Medicine Grand Rounds, University of California, Irvine, CA: TILTS: Tumor Imaging Localization and Therapy System. (1999)
182. Washington Cancer Institute, Washington, DC: Somatostatin Inhibition of Tumor Growth and Angiogenesis. (1999)
183. VIP Speakers Forum, Dallas, TX: Carcinoid Syndrome. (2000)
184. Aventura Hospital, Miami, FL: Angiogenesis/Octreotide. (2000)
185. University of Miami Medical Grand Rounds, Miami, FL: Clinical Approach to Carcinoid Tumors. (2000)
186. Oncology Nursing Society, Miami, FL: Past, Present and Future Use of Octreotide in Oncology. (2000)
187. West Palm Beach Veterans Administration, West Palm Beach, FL: Carcinoid Tumors/Angiogenesis. (2000)
188. University of Miami Endocrinology Grand Rounds, Miami, FL: TILTS: Tumor Imaging Localization and Therapy System. (2000)
189. Martin Memorial Forum, Miami, FL: Angiogenesis. (2000)
190. The Egozi Memorial Lecture, University of Miami, Miami, FL: New Concepts in the Diagnosis and Therapy of Cancer. (2000)
191. Texas Oncology Physicians’ Association, VIP Speakers Forum, Dallas, TX: Angiogenesis and Tumor Growth. (2001)
192. Novartis Oncology VIP Speakers Forum, Baltimore, MD: Current Concepts in GI Uses of Somatostatin Analogs. (2001)
193. Ketchikan Cancer Symposium, Ketchikan, AK: Confessions of a Breast Cancer Heretic, and Neuroendocrine Tumors: From the Basics to the Sublime. (2001)
194. Novartis GEP Advisory Board Meeting, Rome, Italy: Binding and Internalization of Somatostatin Analogs. (2001)
195. Carcinoid Wellness Conference, Memorial Medical Center, New Orleans, LA: Introduction to the Basic Science of Carcinoid. (2002)
196. Novartis GEP Advisory Board Meeting, Interlaken, Switzerland: Antibodies to Octreotide: Implications on Medical Treatment, & Antiangiogenesis During Treatment with Somatostatin Analogues. (2002)
197. Novartis Oncology Speakers Bureau, Santa Fe, NM: Octreotide and the Treatment of Tumor and Carcinoid Related Diarrhea. (2002)
198. Novartis Oncology Speakers Bureau, White Sulphur Springs, WV: New Treatment Options for Chemotherapy Induced Diarrhea. (2002)
199. Novartis Oncology Speakers Bureau, Houston, TX: Octreotide – Applications Beyond Carcinoid. (2002)
200. Novartis Oncology Thought Leader Advisory Board Meeting, Sonoma, CA: Anti-angiogenesis as a Mechanism for Anti-Tumor Effects. (2002)
201. Southern California Carcinoid Fighters, UC Irvine Medical Center, Orange County, CA. (2002)
202. IRIST Peptides meeting, Rotterdam, The Netherlands: Angiogenesis. (2002)
203. 6th International Meeting on Neuroendocrine Tumors, Keflavik, Iceland: Anti-angiogenic Effects of Somatostatin Analogues. (2002)
204. Novartis Oncology Speakers Bureau, Montauk Island, NY: Rationale for Using Sandostatin in Secretory and Chemo-Induced Diarrhea”. (2002)
205. Novartis Oncology Speakers Bureau, Brunswick, GA: The Use of Octreotide in Carcinoid Tumors and the Carcinoid Syndrome: Implications for Other Causes of Secretory Diarrhea”. (2002)
206. The APDS 13th Annual Surgical Basic Science Course, New Orleans, LA: GI Hormones. (2002)
207. Novartis Oncology Speakers Bureau, Augusta, GA: Antitumor and Antiangiogenic Effects of Somatostatin Analogues”. (2002)
208. Novartis Oncology Speakers Bureau, Brookdale, NY: Tumor Board - Chemotherapy-Induced Diarrhea. (2002)
209. Novartis Oncology Speakers Bureau, Queens, NY: Tumor Board - Chemotherapy-Induced Diarrhea. (2002)
210. Novartis Oncology Speakers Bureau, Manhasset, NY: Grand Rounds - Chemotherapy-Induced Diarrhea. (2002)
211. LSUHSC Dept of Surgery, New Orleans, LA: Grand Rounds – Pheochromocytomas – Diagnosis and Preoperative/Intraoperative Management. (2002)
212. St. Vincent Catholic Medical Centers (Novartis Speakers Bureau), Queens, NY: Tumor Conference – Manifestations and Management of Neuroendocrine Tumors. (2003)
213. Medical College of Georgia (Novartis Speakers Bureau), Augusta, GA: GI Surgery Conference – Antitumor and Antiangiogenic Effects of Octreotide Therapy in Neuroendocrine Malignancies. (2003)
214. The Medical Center of Georgia (Novartis Speakers Bureau), Columbus, GA: Grand Rounds – Neuroendocrine Tumors of the GI Tract: Islet Cell and Carcinoid Tumors. (2003)
215. American Hepato-Pancreato-Biliary Association (AHPBA) Congress, Miami, FL: Non-surgical Management of Neuroendocrine Tumors. (2003)
216. Carcinoid Cancer Texas Support at Baylor Sammons Cancer Center, Dallas, TX: The Use of Somatostatin Analogs in the Management of Neuroendocrine Tumors. (2004)
217. Current and Future Clinical Trends in Neuroendocrine Tumors (Novartis Consultancy Meeting), Amelia Island, FL: Metastatic and Non-Metastatic Disease. (2004)
218. American Society of Clinical Oncology Annual Meeting, New Orleans, LA: Somatostatin Analogs: Advanced Strategies in Detection and Treatment. (2004)
219. Network for Medical Communication & Research, Challenging Cases in Gastrointestinal Cancer, Boston, MA. (2004)
220. Novartis Regional Consultants Roundtable, Oncology 2004: A Focus on the Novartis Oncology Portfolio, Chicago, IL. (2004)
221. Network for Medical Communication & Research, Challenging Cases in Colorectal Cancer, Chicago, IL. (2004)
222. University of Louisville Health Sciences Center, Multi-Modality Conference, Louisville, KY: Treatment Advances in Neuroendocrine Tumors. (2005)
223. Health Sciences Center for Continuing Education, Pathology Workshops, Optimal Diagnosis of Rare Gastrointestinal Tumors, Houston, TX. (2005)
224. ENETS Conference In Neuroendocrine Tumors, Warsaw, Poland. (2005)
225. Mercy Medical Center Tumor Conference, Akron, OH: New Concepts in the Diagnosis and Management of Neuroendocrine Tumors. (2005)
226. ECCO 13, Paris, France: Blood Levels of Octreotide: Can They Be Markers of Success? (2005)
227. Carcinoid Cancer Awareness Network, N. Bellmore, NY: Diagnosis and Management of NETS. (2005)
228. Rex Oncology Conference (Novartis Speakers Bureau), Raleigh, NC: Neuroendocrine Tumors: What You Need to Know About Their Diagnosis & Therapy. (2005)
229. Presbyterian Cancer Center (Novartis Speakers Bureau), Charlotte, NC: Diagnosis and Management of NETS. (2006)
230. Tumor Board (Novartis Speakers Bureau), Nashville, TN: Diagnosis and Management of NETS. (2006)
231. Mercy General Hospital, (Novartis Speakers Bureau), Sacramento, CA: Diagnosis and Management of NETS. (2006)
232. CCAN, New York, NY: Diagnosis and Management of NETS. (2006)
233. Cedars-Sinai Medical Center, Lost Angeles, CA: Management and Diagnosis of Neuroendocrine Tumors. (2007)
234. SAGES Annual Meeting, Las Vegas, NV: CON: Metastatic Neuroendocrine Carcinoma: A Multimodality Approach is Warranted. (2007)
235. Annual Meeting-Louisiana Chapter, American College of Surgeons, New Orleans, LA: The Effect of Hypoxia on Initiation of Angiogenesis and Neovessel Growth. (2007)
236. Carcinoid Cancer Awareness Network Inc, Pasadena, CA: The Diagnosis and Treatment of Carcinoid Cancer What Patients Need to Know. (2007)
237. Carcinoid Cancer Awareness Network, University of Michigan, Ann Arbor, MI: The Diagnosis and Treatment of Carcinoid Cancer What Patients Need to Know. (2007)
238. Carcinoid Cancer Awareness Network, Melville, IL: The Diagnosis and Treatment of Carcinoid Cancer What Patients Need to Know. (2007)
239. Carcinoid Cancer Awareness Network, Webinar: The Diagnosis and Treatment of Carcinoid Cancer What Patients Need to Know. (2007)
240. Louisiana Cancer Research Consortium Retreat; From the Bench to the Bedside and Back Again: Tracking the Failure of Sandostatin LAR. (2008)
241. Indiana University Transplant Center: Indianapolis, IN: New Paradigms to Increase Survival in NET Patients. (2011)
242. Carcinoid Cancer Foundation Symposium; New York, NY: From the Bedside to the Laboratory and Back Again (2011)
243. Carcinoid Cancer Awareness Network; Indianapolis, IN: A Personalized Approach to NET Care (2011)
244. Carcinoid Cancer Awareness Network; Dallas, TX: A Personalized Approach to NET Care (2011)
245. Carcinoid Neuroendocrine Tumor Society Canada (CNETS), Ottawa, Ontario. Testing liver tumours: what is available? (2012)
246. Carcinoid Neuroendocrine Tumor Society Canada (CNETS), Ottawa, Ontario. What’s new in NET research? Are all of your tumours the same? (2012)
247. Colorado Carcinoid Cancer Support Group. Run For Hope, Fort Collins, CO. New Advances in the Diagnosis and Treatment of NETs. (2012)
248. National NET Patient Conference. New Orleans, LA. Development and Validation of NET Markers: Pancreastatin and Plasma 5-HIAA. (2012)
249. National NET Patient Conference. New Orleans, LA. Tissue Testing- What’s NEW, What’s OLD, Where is the future going? (2012)

**Editorial Posts and Activities:**

**Reviewer**

NIH Small Business Grants Study Section (1994-1997)

External Grant Application Reviewer-National Cancer Institute of Canada (2002)

**Editorial and Advisory Boards**

American Program Directors in Surgery Computerized Surgical Education Program CSEP Oncology Section Editor, American College of Surgeons SESAP, PMP Co-Chairman, Section #1

International Journal of Pancreatology

Associate Editor-in-Chief, Peptide Therapy: Index & Reviews

National medical Information Network

Southern Medical Association Annual Clinic Review Course

American Program Directors in Surgery Annual Clinical Review Course

Novartis GEP Neuroendocrine Tumor International Advisory Board

GI Council of Inter Sciences Institute

Pharmacology and Therapeutics

**Ad Hoc Reviewer**

Digestive Diseases and Sciences

Journal of Surgical Research

Journal of Cellular Physiology

Cancer Research

Clinical Cancer Research

Journal of Vascular Surgery

British Journal of Cancer

Annals of Surgical Oncology

The Journal of Pharmacology and Experimental Therapeutics

Digestion

Cancer

Journal of Nuclear Medicine

**Military Service**

Lt. Commander in Public Health Service (1977-1979; Honorable Discharge)